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The present invention relates to compositions and methods
for controlling nematode infestation of plants. In particular,
the present invention provides vectors comprising sequences
designed to control nematodes by RNA interference (RNAi)
and transgenic plants transformed with Such vectors.
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Figure 1
SEQ ID NO:1
GATGANCATTTATTAACGCACAACAACAATACAATTACATANGGCAACAATCAAATATA
CATTCATTTGAAGTGATGATCACAGAAATTTACATACAGATACAACAATTTACATGATG
GGGGACAAAATGACAATTTTGGGACGGTGGGATGGGATCCTATCATGTCCATGTTGAGG
TGACGAAGCATCCTTCCATCAGACGTTGTACTCGATCGGCAAGTTCTTGCGGCGCACCA
TCCCGTCTCCCTGGAACCACTCGAGCTTGAACGTGGTGTCGGCTGGGTCCGGTGTGTTG
GTCCACTCCGCGGCGGCGGCGGCGCCGGGCGGTTCCGGCACGTTGGTCCACGCCACGGT
CACACGGTCGTCCTTGGTGTCCTCGCTGCCGGGGTCGAAGGCGTCNCAGAANACGGCCA

CGTTGACAGATTCCTTTGGGCCGANCACTCCGTCCGGCGGGTTCATGTTGATNCGCTTC
GGTTTGGTGGTCTTGAAGGCGTAGCCGATGCGCTTCGTCCCAAGGTTGATCACNCNCAA
GTAGTANATGGCTTTGTTGTCGAAGGNACGTTGNAANAGATCTTCTGCGTGGGCATTGT

TGCGACGTCCTCTGGTGGAAGTTGCGCCATTGCTGTTGTTGTCGCTGTTGTCGGGCTGG
CTTTGTGGGTGCTTGATGTGTGATCGTTGAGAGCGTTGCTTGAAGTGTTGCTGCTATGC
TGCTGAGTGAGGGGAATGTGCAAAATCCACCTCCTTATATACAAAATTCGGGTGCAAAA
ATTCATGCAGCAAAAAAAAAGTGTATAAAAGGCGACGGTTTTCTTCACTTTTCACCAGT
GCCAGCCAGCCTTCAACTCAACGCAACATCAACACCAGTGCGCGCCAAGCTCGTCTACA
CATTTCGTCGCGACAACTCATCACTGATCACAGAAATTTACATACAGATACAACAATTT
ACATGATGGGGGACAAAATGACAATTTTGGGACGGTGGGATGGGATCCTATCATGTCCA
TGTTGAGGTGACGAAGCATCCTTCCATCAGACGTTGTACTCGATCGGCAAGTTCTTGCG
GCGCACCATCCCGTCTCCCTGGAACCACTCGAGCTTGAACGCGGTGACCGGCAGGGCCC
GGCGTGTTGGTCCACTCCACGGCGGCGGTGGCGCCGGGAGGCTNCNCGTGTTGGTCCAC
TCCACGGTCACACGGTCGCCCTTGGGTGTCCTCGCTTNACCTNCNTNTNCGTTTNNNNT
GNTATTTTGCCGNACTGN
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Figure 3
SEQ ID NO:5
CTGCA GGCCTTCAAGACCACCAAACCGAAGCGNATCAACATGAACCCGCC

GGACGGAGTGNTCGGCCCAAAGGAATCTGTCAACGTGGCCGTNTTCTGNG
ACGCCTTCGACCCCGGCAGCGAGGACACCAAGGACGACCGTGTGACCGTG
GCGTGGACCAACGTGCCGGAACCGCCCGGCGCCGCCGCCGCCGCGGAGTG
GACCAACACACCGGACCCAGCCGACACCACGTTCAAGC TCGAG
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Figure 5
SEQ ID NO:9
5

CCAACCCTGCACAAAATGCTATGATGGGACATCGTGTTAAGGCATGACTGTT
TTATTTGCAATTGTTATTTTGGATTATTACGATAGATCTTACCTTGGTCGACTT
TTCGTATGAATTTGTCCGTCACAACCCCTTACAATGCTGATTTTGACGGGGAT
GAAATGAATTAGCACCTTCCGCAATCACTGGAGACACGGGCAGAAATAAACG
AAATTGCGATGGTTTTTATTAATTTAAAGCACCAAATATAACCCTTACCTTTT
CTCTAAAAAGGCATCTCGACAGTTAATTACGCCACAGGCCAACAAGCCAGTG
ATGGGAATTGTGCAGGACACATTGACCGCAGTTCGAATGATGACTAAACGCG
ACGTTTTTATTGATTACGCTCGTCTCATGGATTTGTTGATGCATTTGCCAAATT
GGGATGGAAAAATTCCGCAGCCAGCGATAATCAA ACCCAAGCCACTTTGGAC
CGGAAAACAAGTGTTTACAAAGATAATTCCAGGTTTTGTCAAATGAAACTTTT
CCTCCATTCTTTGTTTTGTTCTAACTAAGGCAGTGTCAATGTTATCCGAACAC
ATTCGACCCATCCGGACGACGAAGACAGCGGACCATACAAATGGATTTCCCC
TGGCGACACCAAAGTGCTCATTGAGAACAGCGAACTTCTCTCTGGGATAATT
TGTTCCAAAACTGTTGGCAGAGGTTCCNGAAACCTTCTTCACATTGTCGCATT
AGAATTGGGTCATCAAATTGCTGCCGAGTTATATGCCA ACATACAAACTGTT
ATAAACGCATGGCTTCTCGCCGAGGGACACACCATTGGAATTGGTTTCCAATT
TTACTTTTATTTACAATAATTTTGTTTAACTCTCAGGTGACACAATTGCTGATA
CTTCCACCTACAGAGATATCCAGGAGACCATAAGAAAGGCCAAACAGGATGT

CATTGATGTTATCGAGAAAGCTCACAACGATGATNCTCGAGCCGACTNCCCG
GGAACACACTTCGACAGACTTCGAAAATCAAGTGAACCGAATTNCTG-3
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Figure 6
SEQ ID NO:10
5’-

GGCAGTGTCAATGTTATCCGAACACATTCGACCCATCCGGACGACGAAGACA
GCGGACCATACAAATGGATTTCCCCTGGCGACACCAAAGTGCTCATTGAGAA
CAGCGAACTTCTCTCTGGGATAATTTGTTCCAAAACTGTTGGCAGAGGTTCCN
GAAACCTTCTTCACATTGTCGCATTAGAATTGGGTCATCAAATTGCTGCCGAG

TTATATGCCA ACATACAAACTGTTATAAACGCATGGCTTCTCGCCGAGGGAC
ACACCATTGGAATTGGT-3
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Figure 7
SEQ ID NO:13
Antisense fragment-285bp

279bp exon region from above showing the RP2 KpnF1B and RP2 BamirB primers:
5

GGCAGTGTCAATGTTATCCGAACACATTCGACCCATCCGGACGACGAAGACA
GCGGACCATACAAATGGATTTCCCCTGGCGACACCAAAGTGCTCATTGAGAA
CAGCGAACTTCTCTCTGGGATAATTTGTTCCAAAACTGTTGGCAGAGGTTCCN
GAAACCTTCTTCACATTGTCGCATTAGAATTGGGTCATCAAATTGCTGCCGAG
TTATATGCCAACATACAAACTGTTATAAACGCATGGCTTCTCGCCGAGGGAC
ACACCATTGGAATTGGT-3
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Figure 8
SEQ ID NO:14

Reverse complement of the 279bp exon fragment showing the RP2 KpnF1B and
RP2 BamRB primers:
5

ACCAATTCCAATGGTGTGTCCCTCGGCGAGAAGCCATGCGTTTATAACAGTTT
GTATGTTGGCATATAACTCGGCAGCAATTTGATGACCCAATTCTAATGCGACA
ATGTGAAGAAGGTTTCNGGAACCTCTGCCAACAGTTTTGGAACAAATTATCC
CAGAGAGAAGTTCGCTGTTCTCAATGAGCACTTTGGTGTCGCCAGGGGAAAT
CCATTTGTATGGTCCGCTGTCTTCGTCGTCCGGATGGGTCGAATGTGTTCGGA
TAACATTGACACTGCC-3
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Figure 9
Cloning strategy for sense RNA polymerase I sequence
Kpn I

5

Bam HI

BamHI Kon I

D

Bam H. I

35s promoter

Kpp. I

Antisense fragment
fragment
Antisense

5

-O-

Nosterminator
3.
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Figure 10
SEQ ID NO:17

GGCAGTGTCAATGTTATCCGAACACATTCGACCCATCCGGACGACGAAG
ACAGCGGACCATACAAATGGATTTCCCCTGGCGACACCAAAGTGCTCATTGA
GAACAGCGAACTTCTCTCTGGGATAATTTGTTCCAAAACTGTTGGCAGAGGTT
CCNGA AACCTTCTTCACATTGTCGCATTAGAATTGGGTCATCAAATTGCTGCC
GAGTTATATGCCA ACATACAAACTGTTATAAACGCATGGCTTCTCGCCGAGG
GACACACCATTGGAATTGGT
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Figure 11

Cloning strategy for sense RNA polymerase II sequence
Kpn I

Sac I

Kpn I

Sac I

N
243bp

42bp

243bp

35S

Nos

<--

v

-D

Double Stranded RNA Production
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Figure 12
SEQ ID NO:18
Sp6
CAAGAAACGATGGTCCCAGGTGATGTACATGTACTTTTTGCTCGGGCATCGAATTATGG
ACTCACATTTGAGCGTAGAAGACAAACAATTGCAGGTCTTTTGAGCCTAAATTTTGCCC
TCGTGGAATCTGTGCAATAATTCAATGTTCGCACCGATGCTTAGGCTGACAACACATAT
ATTCTCGCCATTGATGGCGATTCCAAATTCGAACCAGCGGCAGTGATTCGTCTTTTACA
TCTGATGAACTTGAAAAGCGACGTTGGCTGTGCGTGCGGAAGAATCCATCCGATTGGAG
AAGGTGTGCTATCCTTCCCATTAATGGTGAATTTCTTACCATTCCCCAGGGGTCATGGT
TTGGTACCAAAAGTTCGAGTACGCAATCGCCCATTGGTTCCAAAAGGCTGCTGAGCATG
TGTTCGGCTGTGTTTTGTGTGCCCCCGGTAGCTTCTCTCTGTTTCGTGCTTCTGCTCTC
ATGGATGACAATGTGATGCACAAATACACCAAAANTGCCTCCGAACCNACGACNATTTT
GTTCAGTATTGATCAAGGCGAAGACCCGAGGA-T7
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Figure 13. Soybean cyst production on transgenic lines vs. control plants as functional of
cysts per plant.

Experiment 1

Experiment 2
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Experiment 1

Experiment 2

Figure 14. Soybean cyst production on transgenic lines vs. control plants as
functional of cysts per gram of root tissue. “*” indicates data is significant.
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Experiment 2

Figure 15. Soybean cyst nematode egg production on transgenic lines vs.
control plants as an average number of eggs per plant. “*” indicates data is

significant.
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i
Experiment 1

Experiment 2

Figure 16. Soybean cyst nematode egg production on transgenic lines vs. control plants
as an average number of eggs per gram of root. indicates data is significant.
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Experiment 2

Figure 17. Soybean cyst nematode egg production on transgenic lines vs. control plants
as an average number of eggs per cyst.
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sequences designed to control nematodes by RNA interfer
ence (RNAi) and transgenic plants transformed with Such

COMPOSITIONS AND METHODS FOR
CONTROLLING PLANT PARASITIC
NEMATODES

VectOrS.

This application claims the benefit of U.S. Provisional
Application 60/395,153, filed Jul. 10, 2002.
This invention was made with government Support under
Hatch Grant No. KS699 awarded by CRSEES. The Govern
ment has certain rights in the invention.
10

FIELD OF THE INVENTION

The present invention relates to compositions and methods
for controlling nematode infestation of plants or animals. In
particular, the present invention provides vectors comprising
sequences designed to control nematodes by RNA interfer
ence (RNAi) and transgenic plants transformed with Such

15

VectOrS.

BACKGROUND OF THE INVENTION

The soybean cyst nematode (SCN), Heterodera glycines, is
the primary biotic factor limiting Soybean production in the
United States, accounting for 40% of total disease losses
(Wrather, J. A., Anderson, T. R., Arsyad, D. M., Gai, J.,
Ploper, L. D., Porta-Puglia, A., Ram, H. H., Yorinori, J. T.
1997. Soybean disease loss estimates for the top 10 soybean
producing countries in 1994. Plant Disease 81:107-110). The
nematode is a relatively recent introduction to Kansas (Sim,
T., IV., and Todd, T. C. 1986. First field observation of the
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soybean cyst nematode in Kansas. Plant Disease 70:603), yet
its present distribution encompasses 40 counties across six
of the nine state districts. Based on the results of an extensive

grower sampling program (SCN Coalition), approximately
10% of the state's soybean production fields are estimated to
be infested with H. glycines, with nematode prevalence in
several areas exceeding 40%. Yield losses in individual
infested fields in Kansas range from 10% to 40%, depending
on environment (Todd, T. C. Schapaugh, W. T., Long, J. H.,
and Holmes, B. 1995. Field response of soybean in maturity
groups III-V to Heterodera glycines in Kansas. Supplement
to the Journal of Nematology 27:628-633.).
Nonhost crops and resistant varieties are the most widely
used management strategies for SCN. Both effectively reduce
nematode population densities, but declines in the North Cen
tral region are relatively slow and elimination unlikely. Resis
tance, while readily available for the most common variants
(races) of SCN, has a narrow genetic base (~85% of resistant
varieties derive their resistance from a single source), and is
limited or unavailable for Some populations. In addition,
adaptation of nematode populations to resistant varieties
poses a significant threat to the long-term management of this
pest (Holmes, B.A., Todd, T. C., and Schapaugh, W. T. 1999.
Effect of resistance source on SCN populations. National
Soybean Cyst Nematode Conference, Orlando, Fla., Jan. 7-8,
1999: Young, L. D. 1998. Managing soybean resistance to
Heterodera glycines. Supplement to the Journal of Nematol
ogy 30:525-529).
Novel approaches to SCN management are needed to
complement current strategies, and prolong the effectiveness
of available resistance genes.
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SUMMARY OF THE INVENTION

The present invention relates to compositions and methods
for controlling nematode infestation of plants or animals. In
particular, the present invention provides vectors comprising

65

Accordingly, in Some embodiments, the present invention
provides transgenic plants comprising heterologous nucleic
acid sequences encoding a double stranded nematode RNA
sequence, wherein said double stranded RNA sequence
inhibits the proliferation of nematodes ingesting said double
Stranded nematode RNA sequence. The present invention is
not limited to any particular expression constructor construct
design. Indeed, the use of a variety of constructs and designs
are contemplated. In some embodiments, the heterologous
nucleic acid sequences are operably linked to the same pro
moter. In other embodiments, the heterologous nucleic acid
sequences are operably linked to separate or different pro
moter sequences. In still other embodiments, the heterolo
gous nucleic acid sequences are separated by a loop sequence.
In some embodiments, the promoter is a tissue specific pro
moter, while in other embodiments the promoter is a consti
tutive promoter. The present invention is not limited to the use
of any particular heterologous nucleic acid sequence. Indeed,
the use of a variety of sequences is contemplated, including,
but not limited to those that complementary to an RNA
sequence selected from the group consisting of nematode
Major sperm protein, RNA polymerase II, and Chitin syn
thase RNA sequences. In other embodiments, the sequences
are selected from Tables 1 or 2, supra. Likewise, the present
invention is not limited to heterologous nucleic acid
sequences of any particular length. Indeed, heterologous
nucleic acid sequences of varying lengths may be utilized,
including those from about 21 bases in length to the full
length of the target RNA. In still further embodiments, the
present invention provides plant tissue or material from the
foregoing transgenic plants. The present invention is not lim
ited to any particular tissue or material. Indeed, a variety of
plant tissues and materials are contemplated. Accordingly, in
Some embodiments, the present invention provides seeds,
leaves, roots, or processed materials derived from the forego
ing transgenic plants.
In some embodiments, the present invention provides vec
tors comprising heterologous nucleic acid sequences encod
ing a double stranded nematode RNA sequence, wherein said
double stranded RNA sequence inhibits the proliferation of
nematodes ingesting said double stranded RNA sequence.
The present invention is not limited to any particular vector or
vector design. Indeed, the use of a variety of vectors and
designs are contemplated. In some embodiments, the heter
ologous nucleic acid sequences are operably linked to the
same promoter. In other embodiments, the heterologous
nucleic acid sequences are operably linked to separate or
different promoter sequences. In still other embodiments, the
heterologous nucleic acid sequences are separated by a loop
sequence. In some embodiments, the promoter is a tissue
specific promoter, while in other embodiments the promoter
is a constitutive promoter. The present invention is not limited
to the use of any particular heterologous nucleic acid
sequence. Indeed, the use of a variety of sequences is con
templated, including, but not limited to those that comple
mentary to an RNA sequence selected from the group con
sisting of nematode Major sperm protein, RNA polymerase
II, and Chitin synthase RNA sequences. In some embodi
ments, the double stranded nematode RNA is complementary
to an embryonic lethal phenotype gene. In further embodi
ments, the double stranded nematode RNA is complementary
to a sterile phenotype gene. In other embodiments, the
sequences are selected from Tables 1 or 2, Supra. Likewise,
the present invention is not limited to heterologous nucleic
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3
acid sequences of any particular length. Indeed, heterologous
nucleic acid sequences of varying lengths may be utilized,
including those from about 21 bases in length to the full
length of the target RNA. In still further embodiments, the
present invention provides a transgenic plant comprising the
foregoing vectors. In other embodiments, the present inven
tion provides animal feeds comprising plant tissue from the
foregoing transgenic plants. In some embodiments, the plant
tissue is selected from seeds and leaves. In still further

embodiments, the present invention provides pharmaceutical
compositions comprising materials derived from the forego
ing transgenic plants.
Instill further embodiments, the present invention provides
methods of creating transgenic plants comprising transfect
ing a plant or plant tissue with the foregoing vector. In other
embodiments, the present invention provides the transgenic
plant produced by this process. In some embodiments, the
methods further comprises harvesting the transgenic material
and using the transgenic plant material to produce a pharma
ceutical composition or animal feed. The present invention
also provides the pharmaceutical compositions and animal
feeds produced by these processes.
In still other embodiments, the present invention provides
methods for controlling nematodes comprising: a) providing
transgenic plant tissue comprising heterologous DNA
sequences encoding a double stranded nematode RNA; and b)
growing said transgenic plant so that said double stranded
nematode RNA is expressed in plant tissue; wherein the pro
liferation of nematodes feeding on said plant tissue is reduced
as compared to nematodes feeding on non-transgenic plant
tissue. The present invention is not limited to inhibiting the
proliferation of any particular type of nematodes. Indeed, the
inhibition of proliferation of a number of different types of
nematodes is contemplated, including, but not limited to plant
parasitic nematodes and animal parasitic nematodes. In some
preferred embodiments, the double stranded nematode RNA
is orally active to prevent the proliferation of nematodes.
Accordingly, in Some embodiment the nematodes orally
ingest said double stranded nematode RNA. The present
invention is not limited to the use of any particular expression
vector or vector design. Indeed, the use of a variety of vectors
and designs are contemplated. In some embodiments, the
heterologous nucleic acid sequences are operably linked to
the same promoter. In other embodiments, the heterologous
nucleic acid sequences are operably linked to separate or
different promoter sequences. In still other embodiments, the
heterologous nucleic acid sequences are separated by a loop
sequence. In some embodiments, the promoter is a tissue
specific promoter, while in other embodiments the promoter
is a constitutive promoter. The present invention is not limited
to the use of any particular heterologous nucleic acid
sequence. Indeed, the use of a variety of sequences is con
templated, including, but not limited to those that comple
mentary to an RNA sequence selected from the group con
sisting of nematode Major sperm protein, RNA polymerase
II, and Chitin synthase RNA sequences. In some embodi
ments, the double stranded nematode RNA is complementary
to an embryonic lethal phenotype gene. In further embodi
ments, the double stranded nematode RNA is complementary
to a sterile phenotype gene. In other embodiments, the
sequences are selected from Tables 1 or 2, Supra. Likewise,
the present invention is not limited to heterologous nucleic
acid sequences of any particular length. Indeed, heterologous
nucleic acid sequences of varying lengths may be utilized,
including those from about 21 bases in length to the full
length of the target RNA. In some embodiments, the double
Stranded nematode RNA is complementary to an embryonic
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lethal phenotype gene. In further embodiments, the double
stranded nematode RNA is complementary to a sterile phe
notype gene. In still further embodiments, the nematodes
feeding on said plant tissue are killed.
In some embodiments, the present invention provides a
transgenic plant expressing a heterologous double stranded
nematode RNA sequence at a level Such that nematodes
ingesting said heterologous double stranded nematode RNA
sequences exhibit decreased proliferation as compared to
nematodes feeding on non-transgenic plants.
Instill further embodiments, the present invention provides
pharmaceutical compositions comprising plant material
derived from the foregoing transgenic plants.
In some embodiments, the present invention provides for
the use of transgenic plant material comprising a double
stranded nematode RNA sequence to inhibit the proliferation
of parasitic nematodes in an animal or plant host.
Instill further embodiments, the present invention provides
compositions according to the claims as Substantially
described in the application herein with reference to the fig
ures and/or the specification.
DESCRIPTION OF THE FIGURES

25
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FIG. 1 is the sequence for H. glycines Major sperm protein
(SEQID NO:1).
FIG. 2A is a subsequence of H. glycines Major sperm
protein (SEQ ID NO:4).
FIG. 2B is a subsequence of H. glycines Major sperm
protein (SEQ ID NO:45).
FIG. 3 is the reverse complement (SEQID NO:5) of SEQ
ID NO:4.
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FIG. 4 is the assembled MSPi sequence (SEQID NO:6).
FIG. 5 is the sequence for H. glycines RNA polymerase II
(SEQ ID NO:9).
FIG. 6 provides a 279 base pair exon (SEQIDNO:10) from
the RNA polymerase II gene of H. glycines.
FIG. 7 is a 285 bp sequence (SEQ ID NO:13) prepared
from SEQID NO:10.
FIG. 8 is the reverse complement (SEQID NO:14) of SEQ
ID NO:13.
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FIG. 9 provides a pictorial representation of the cloning
strategy for the RNA polymerase II RNAi construct.
FIG.10 provides the sense sequence (SEQID NO:17) used
in the RNA polymerase II RNAi construct.
FIG. 11 provides a pictorial depiction of the cloning strat
egy for the RNA polymerase II RNAi construct.
FIG. 12 provides the sequence for H. glycines Chitin syn
thase.

FIG. 13 provides a graph of soybean cyst production on
transgenic lines vs. control plants as functional of cysts per
plant.
FIG. 14 provides a graph of Soybean cyst production on
transgenic lines vs. control plants as functional of cysts per
gram of root tissue. “*” indicates data is significant.
FIG. 15 provides a graph of soybean cyst nematode egg
production on transgenic lines vs. control plants as an average
number of eggs per plant. “*” indicates data is significant.
FIG. 16 provides a graph of soybean cyst nematode egg
production on transgenic lines vs. control plants as an average
number of eggs per gram of root. “*” indicates data is signifi
Cant.
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FIG. 17 provides a graph of soybean cyst nematode egg
production on transgenic lines vs. control plants as an average
number of eggs per cyst.
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5
DEFINITIONS

To facilitate an understanding of the present invention, a
number of terms and phrases as used herein are defined
below:

The term “plant is used in it broadest sense. It includes,
but is not limited to, any species of woody, ornamental or
decorative, crop or cereal, fruit or vegetable plant, and pho
tosynthetic green algae (e.g., Chlamydomonas reinhardtii). It
also refers to a plurality of plant cells that are largely differ
entiated into a structure that is present at any stage of a plants
development. Such structures include, but are not limited to,
a fruit, shoot, stem, leaf, flower petal, etc. The term “plant

5

10

tissue' includes differentiated and undifferentiated tissues of

plants including those present in roots, shoots, leaves, pollen,
seeds and tumors, as well as cells in culture (e.g., single cells,
protoplasts, embryos, callus, etc.). Plant tissue may be in
planta, in organ culture, tissue culture, or cell culture. The
term "plant part as used herein refers to a plant structure, a
plant organ, or a plant tissue.
The term “crop' or “crop plant' is used in its broadest
sense. The term includes, but is not limited to, any species of
plant or algae edible by humans or used as a feed for animals
or used, or consumed by humans, or any plant or algae used in
industry or commerce.
The term plant cell “compartments or organelles' is used in

15

Sequences.

The term “host cell refers to any cell capable of replicating
and/or transcribing and/or translating a heterologous gene.
The term "heterologous, when used in reference to DNA
sequences or genes, means a DNA sequence encoding a pro
tein, polypeptide, RNA, or a portion of any thereof, whose
exact amino acid sequence is not normally found in the host
cell, but is introduced by standard gene transfer techniques.
25

The term “nematode' as used herein refers to worms that

are members of the phylum Nemata.
The term “RNA interference’ or “RNAi refers to the

its broadest sense. The term includes but is not limited to, the

endoplasmic reticulum, Golgi apparatus, trans Golgi net
work, plastids including chloroplasts, proplastids, and leuco
plasts, sarcoplasmic reticulum, glyoxysomes, mitochondrial,
chloroplast, and nuclear membranes, and the like.
As used herein, the term “Major sperm protein (MSP)”
when used in reference to a protein or nucleic acid refers to a
protein or nucleic acid encoding a protein that shares greater
than about 50% identity with any of SEQID NOS: 1,4-6, and
25-30. Thus, the term MSP encompasses both proteins that
are identical to wild-type MSP and those that are derived from
wild type MSP protein (e.g., variants of MSP).
As used herein, the terms "Major sperm protein gene' and
“Major sperm protein nucleic acid sequence” refer to the full
length H. glycines Major sperm protein sequence, as well as
sequence provided as SEQ ID NOS: 1, 4-6, and 25-30,
sequences which bind to SEQ ID NOS: 1, 4-6, and 25-30
under conditions of high Stringency, and nematode Major
sperm protein sequences available in public databases. These
terms encompass fragments of the MSP sequences and
include DNA, cDNA, and RNA (e.g., mRNA) sequences.
As used herein, the term “RNA polymerase II” when used
in reference to a protein or nucleic acid refers to a protein or
nucleic acid encoding a protein that shares greater than about
50% identity with any of SEQID NOS: 9, 10, 13, 14, 17 and
31-37. Thus, the term RNA polymerase II encompasses both
proteins that are identical to wild-type RNA polymerase II
and those that are derived from wild type RNA polymerase II
protein (e.g., variants of RNA polymerase II).
As used herein, the terms “RNA polymerase II gene' and
“RNA polymerase II nucleic acid sequence” refer to the full
length H. glycines RNA polymerase II protein sequence, as
well as sequence provided as SEQID NOS: SEQID NOS:9,
10, 13, 14, 17 and 31-37, sequences which bind to SEQ ID
NOS: SEQID NOS: 9, 10, 13, 14, 17 and 31-37 under con
ditions of high Stringency, and nematode RNA polymerase II
sequences available in public databases. These terms encom
pass fragments of the RNA polymerase II sequences and
include DNA, cDNA, and RNA (e.g., mRNA) sequences.
As used herein, the term "Chitin synthase' when used in
reference to a protein or nucleic acid refers to a protein or

6
nucleic acid encoding a protein that shares greater than about
50% identity with any of SEQID NOS: 18 and 38-44. Thus,
the term Chitin synthase encompasses both proteins that are
identical to wild-type Chitin synthase and those that are
derived from wild type Chitin synthase protein (e.g., variants
of Chitin synthase).
As used herein, the terms “Chitin synthase gene' and
“Chitin synthase nucleic acid sequence” refer to the full
length H. glycines Chitin synthase protein sequence, as well
as sequence provided as SEQ ID NOS: 18 and 38-44,
sequences which bind to SEQID NOs: SEQID NOS: 18 and
38-44 under conditions of high Stringency, and nematode
Chitin synthase sequences available in public databases.
These terms encompass fragments of the Chitin synthase
sequences and include DNA, cDNA, and RNA (e.g., mRNA)

30
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silencing or decreasing of gene expression by iRNA or siR
NAS. It is the process of sequence-specific, post-transcrip
tional gene silencing in animals and plants, initiated by iRNA
that is homologous in its duplex region to the sequence of the
silenced gene. The gene may be endogenous or exogenous to
the organism, present integrated into a chromosome or
present in a transfection vector that is not integrated into the
genome. The expression of the gene is either completely or
partially inhibited. RNAi may also be considered to inhibit
the function of a target RNA; the function of the target RNA
may be complete or partial.
The term “interfering RNA (iRNA) refers to a double

40

stranded RNA molecule that mediates RNA interference

45

(RNAi). At least one strand of the duplex or double-stranded
region of an iRNA is substantially homologous to or Substan
tially complementary to a target RNA molecule. The strand
complementary to a target RNA molecule is the “antisense
strand; the strand homologous to the target RNA molecule is
the “sense strand, and is also complementary to the iRNA
antisense Strand. iRNAS may also contain additional
sequences; non-limiting examples of such sequences include
linking sequences, or loops, as well as stem and other folded

50 Structures.
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The iRNA can serve as a source of siRNA. siRNAs gener
ally comprise a duplex, or double-stranded region, of about
18-25 nucleotides long; often siRNAs contain from about two
to four unpaired nucleotides at the 3' end of each strand. At
least one strand of the duplex or double-stranded region of a
siRNA is substantially homologous to or substantially
complementary to a target RNA molecule. The strand
complementary to a target RNA molecule is the “antisense
strand; the strand homologous to the target RNA molecule is
the “sense strand, and is also complementary to the siRNA
antisense Strand. SiRNAS may also contain additional
sequences; non-limiting examples of such sequences include
linking sequences, or loops, as well as stem and other folded
structures. SiRNAS appear to function as key intermediaries in
triggering RNA interference in invertebrates and in verte
brates, and in triggering sequence-specific RNA degradation
during post-transcriptional gene silencing in plants.
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has a greater than 60% sequence identity, and more preferable
greater than 75% sequence identity, and still more preferably
greater than 90% sequence identity, with a reference

7
The term “target RNA molecule' refers to an RNA mol
ecule to which at least one strand of the short double-stranded

region of an iRNA is homologous or complementary. Typi
cally, when Such homology or complementary is about 100%,
the siRNA is able to silence or inhibit expression of the target
RNA molecule. Although it is believed that processed mRNA
is a target of siRNA, the present invention is not limited to any
particular hypothesis, and Such hypotheses are not necessary
to practice the present invention. Thus, it is contemplated that
other RNA molecules may also be targets of siRNA. Such
targets include unprocessed mRNA, ribosomal RNA, and
viral RNA genomes.
As used herein, the term “loop sequence” refers to a nucleic
acid sequence that is placed between two nucleic sequences
that are complementary to each other and which forms a loops
when the complementary nucleic acid sequences hybridize to

5

to a polypeptide refer to an amino acid sequence that differs
by one or more amino acids from another, usually related
polypeptide. The variant may have "conservative changes,
10

15

one another.

The term “nematode target RNA as used herein refers to
an RNA that is expressed in a nematode.
The term “double stranded nematode RNA sequence'
refers to an iRNA that is specific for a nematode target RNA.
The term “inhibits the proliferation of nematodes' refers to
a reduction in nematode parasitism of a host organism. The
inhibition of proliferation can be mediated in a variety of
ways, including, but not limited to, decreasing the fitness of
the nematode by decreasing or inhibiting the expression of
genes required for nematode fitness (e.g., RNA polymerase
II) or inhibiting genes required for reproduction (e.g., Major
sperm protein or Chitin synthase). A variety of assays may be
used to measure proliferation, including, but not limited to
measuring the number of roots cysts that develop in plants
exposed to nematodes.
As used herein, the term "orally active to prevent the pro

25
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liferation of nematodes' refers to a double stranded nematode

RNA sequence that inhibits the proliferation of nematodes
when orally ingested by the nematodes.
The terms “protein’ and “polypeptide' refer to compounds
comprisingamino acids joined via peptide bonds and are used
interchangeably.
As used herein, “amino acid sequence” refers to an amino
acid sequence of a protein molecule. “Amino acid sequence'
and like terms, such as “polypeptide' or “protein.” are not
meant to limit the amino acid sequence to the complete, native
amino acid sequence associated with the recited protein mol
ecule. Furthermore, an 'amino acid sequence can be
deduced from the nucleic acid sequence encoding the protein.
The term “portion' when used in reference to a protein (as
in “a portion of a given protein') refers to fragments of that
protein. The fragments may range in size from four amino
acid residues to the entire amino sequence minus one amino
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calculation takes into account those amino acid residues that

are identical and in the same relative positions in their respec
tive larger sequences. Calculations of identity may be per
formed by algorithms contained within computer programs.
The term “homolog’ or “homologous' when used in ref
erence to a polypeptide refers to a high degree of sequence
identity between two polypeptides, or to a high degree of
similarity between the three-dimensional structure or to a
high degree of similarity between the active site and the
mechanism of action. In a preferred embodiment, a homolog

wherein a Substituted amino acid has similar structural or

chemical properties (e.g., replacement of leucine with isoleu
cine). More rarely, a variant may have “non-conservative'
changes (e.g., replacement of a glycine with a tryptophan).
Similar minor variations may also include amino acid dele
tions or insertions (in other words, additions), or both. Guid
ance in determining which and how many amino acid resi
dues may be substituted, inserted or deleted without
abolishing biological activity may be found using computer
programs well known in the art, for example, DNAStar soft
ware. Variants can be tested in functional assays. Preferred
variants have less than 10%, and preferably less than 5%, and
still more preferably less than 2% changes (whether substi
tutions, deletions, and so on).
The term “gene' refers to a nucleic acid (e.g., DNA or
RNA) sequence that comprises coding sequences necessary
for the production of an RNA, or a polypeptide or its precur
Sor (e.g., proinsulin). A functional polypeptide can be
encoded by a full length coding sequence or by any portion of
the coding sequence as long as the desired activity or func
tional properties (e.g., enzymatic activity, ligand binding,
signal transduction, etc.) of the polypeptide are retained. The
term “portion” when used in reference to a gene refers to
fragments of that gene. The fragments may range in size from
a few nucleotides to the entire gene sequence minus one
nucleotide. Thus, “a nucleotide comprising at least a portion
of a gene' may comprise fragments of the gene or the entire
gene.

acid.

The term “homology' when used in relation to amino acids
refers to a degree of similarity or identity. There may be
partial homology or complete homology (i.e., identity).
“Sequence identity” refers to a measure of relatedness
between two or more proteins, and is given as a percentage
with reference to the total comparison length. The identity

Sequence.
The terms “variant' and “mutant” when used in reference
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The term “gene' also encompasses the coding regions of a
structural gene and includes sequences located adjacent to the
coding region on both the 5' and 3' ends for a distance of about
1kb on either end Such that the gene corresponds to the length
of the full-length mRNA. The sequences which are located 5'
of the coding region and which are present on the mRNA are
referred to as 5' non-translated sequences. The sequences
which are located 3' or downstream of the coding region and
which are present on the mRNA are referred to as 3' non
translated sequences. The term 'gene' encompasses both
cDNA and genomic forms of a gene. A genomic form or clone
of a gene contains the coding region interrupted with non
coding sequences termed “introns' or “intervening regions'
or “intervening sequences.” Introns are segments of a gene
which are transcribed into nuclear RNA (hnRNA); introns
may contain regulatory elements such as enhancers. Introns
are removed or “spliced out from the nuclear or primary
transcript; introns therefore are absent in the messenger RNA
(mRNA) transcript. The mRNA functions during translation
to specify the sequence or order of amino acids in a nascent
polypeptide.
In addition to containing introns, genomic forms of a gene
may also include sequences located on both the 5' and 3' end
of the sequences that are present on the RNA transcript. These
sequences are referred to as “flanking sequences or regions
(these flanking sequences are located 5' or 3' to the non
translated sequences present on the mRNA transcript). The 5'
flanking region may contain regulatory sequences such as
promoters and enhancers that control or influence the tran
Scription of the gene. The 3' flanking region may contain
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sequences that direct the termination of transcription, post
transcriptional cleavage and polyadenylation.
The term "heterologous gene' refers to a gene encoding a
factor that is not in its natural environment (i.e., has been
altered by the hand of man). For example, a heterologous
gene includes a gene from one species introduced into
another species. A heterologous gene also includes a gene
native to an organism that has been altered in Some way (e.g.,
mutated, added in multiple copies, linked to a non-native
promoter or enhancer sequence, etc.). Heterologous genes
may comprise plant gene sequences that comprise cDNA
forms of a plant gene; the cDNA sequences may be expressed
in either a sense (to produce mRNA) or anti-sense orientation
(to produce an anti-sense RNA transcript that is complemen
tary to the mRNA transcript). Heterologous genes are distinguished from endogenous plant genes in that the heterologous
gene sequences are typically joined to nucleotide sequences
comprising regulatory elements such as promoters that are
not found naturally associated with the gene for the protein
encoded by the heterologous gene or with plant gene
sequences in the chromosome, or are associated with portions
of the chromosome not found in nature (e.g., genes expressed
in loci where the gene is not normally expressed).
The term "oligonucleotide' refers to a molecule comprised
of two or more deoxyribonucleotides or ribonucleotides,
preferably more than three, and usually more than ten. The
exact size will depend on many factors, which in turn depends
on the ultimate function or use of the oligonucleotide. The
oligonucleotide may be generated in any manner, including
chemical synthesis, DNA replication, reverse transcription,
or a combination thereof.

The term “an oligonucleotide having a nucleotide
sequence encoding a gene' or “a nucleic acid sequence
encoding a specified polypeptide refers to a nucleic acid
sequence comprising the coding region of a gene or in other
words the nucleic acid sequence which encodes a gene prod
uct. The coding region may be present in either a cDNA,
genomic DNA or RNA form. When present in a DNA form,
the oligonucleotide may be single-stranded (i.e., the sense
strand) or double-stranded. Suitable control elements such as
enhancers/promoters, splice junctions, polyadenylation sig
nals, etc. may be placed in close proximity to the coding
region of the gene if needed to permit proper initiation of
transcription and/or correct processing of the primary RNA
transcript. Alternatively, the coding region utilized in the
expression vectors of the present invention may contain
endogenous enhancers/promoters, splice junctions, interven
ing sequences, polyadenylation signals, etc. or a combination
of both endogenous and exogenous control elements.
The terms “complementary' and “complementarity” refer
to polynucleotides (i.e., a sequence of nucleotides) related by
the base-pairing rules. For example, for the sequence "A-GT” is complementary to the sequence “T-C-A. Complemen
tarity may be “partial.” in which only some of the nucleic
acids bases are matched according to the base pairing rules.
Or, there may be “complete' or “total complementarity
between the nucleic acids. The degree of complementarity
between nucleic acid strands has significant effects on the
efficiency and strength of hybridization between nucleic acid
Strands. This is of particular importance in amplification reactions, as well as detection methods which depend upon bind
ing between nucleic acids.
The term “homology' when used in relation to nucleic
acids refers to a degree of complementarity. There may be
partial homology or complete homology (i.e., identity).
“Sequence identity” refers to a measure of relatedness
between two or more nucleic acids, and is given as a percent
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age with reference to the total comparison length. The iden
tity calculation takes into account those nucleotide residues
that are identical and in the same relative positions in their
respective larger sequences. Calculations of identity may be
performed by algorithms contained within computer pro
grams such as “GAP’ (Genetics Computer Group, Madison,
Wis.) and “ALIGN” (DNAStar, Madison, Wis.). A partially
complementary sequence is one that at least partially inhibits
(or competes with) a completely complementary sequence
from hybridizing to a target nucleic acid is referred to using
the functional term “substantially homologous.” The inhibi
tion of hybridization of the completely complementary
sequence to the target sequence may be examined using a
hybridization assay (Southern or Northern blot, solution
hybridization and the like) under conditions of low strin
gency. A Substantially homologous sequence or probe will
compete for and inhibit the binding (i.e., the hybridization) of
a sequence that is completely homologous to a target under
conditions of low stringency. This is not to say that conditions
of low stringency are such that non-specific binding is per
mitted; low stringency conditions require that the binding of
two sequences to one another be a specific (i.e., selective)
interaction. The absence of non-specific binding may be
tested by the use of a second target which lacks even a partial
degree of complementarity (e.g., less than about 30% iden
tity); in the absence of non-specific binding the probe will not
hybridize to the second non-complementary target.
When used in reference to a double-stranded nucleic acid

sequence Such as a cDNA or genomic clone, the term "sub
30 stantially homologous' refers to any probe which can hybrid
ize to either or both strands of the double-stranded nucleic

acid sequence under conditions of low stringency as
described infra.

The term “hybridization” refers to the pairing of comple
35 mentary nucleic acids. Hybridization and the strength of
hybridization (i.e., the strength of the association between the
nucleic acids) is impacted by Such factors as the degree of
complementary between the nucleic acids, stringency of the
conditions involved, the T of the formed hybrid, and the G:C
40 ratio within the nucleic acids. A single molecule that contains
pairing of complementary nucleic acids within its structure is
said to be “self-hybridized.”
The term “T” refers to the “melting temperature' of a
nucleic acid. The melting temperature is the temperature at
45 which a population of double-stranded nucleic acid mol
ecules becomes half dissociated into single strands. The equa
tion for calculating the T of nucleic acids is well known in
the art. As indicated by standard references, a simple estimate
of the T value may be calculated by the equation: T81.5+
50 0.41 (% G+C), when a nucleic acid is in aqueous Solution at 1
MNaCl (See e.g., Anderson and Young, Quantitative Filter
Hybridization (1985) in Nucleic Acid Hybridization). Other
references include more Sophisticated computations that take
structural as well as sequence characteristics into account for
55 the calculation of T.
As used herein the term “stringency” refers to the condi
tions oftemperature, ionic strength, and the presence of other
compounds such as organic solvents, under which nucleic
acid hybridizations are conducted. With “high stringency’
60 conditions, nucleic acid base pairing will occur only between
nucleic acid fragments that have a high frequency of comple
mentary base sequences. Thus, conditions of “low” strin
gency are often required with nucleic acids that are derived
from organisms that are genetically diverse, as the frequency
65 of complementary sequences is usually less.
“High stringency conditions” when used in reference to
nucleic acid hybridization comprise conditions equivalent to
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binding or hybridization at 42°C. in a solution consisting of
5xSSPE (43.8 g/l NaCl, 6.9 g/l NaHPO HO and 1.85 g/1
EDTA, pH adjusted to 7.4 with NaOH), 0.5% SDS, 5xDen
hardt’s reagent and 100 ug/ml denatured salmon sperm DNA
followed by washing in a solution comprising 0.1 xSSPE,
1.0% SDS at 42°C. when a probe of about 500 nucleotides in
length is employed.
“Medium stringency conditions” when used in reference to
nucleic acid hybridization comprise conditions equivalent to
binding or hybridization at 42°C. in a solution consisting of
5xSSPE (43.8 g/l NaCl, 6.9 g/l NaH2POHO and 1.85 g/1
EDTA, pH adjusted to 7.4 with NaOH), 0.5% SDS, 5xDen
hardt’s reagent and 100 ug/ml denatured salmon sperm DNA
followed by washing in a solution comprising 1.0xSSPE,
1.0% SDS at 42°C. when a probe of about 500 nucleotides in
length is employed.
“Low Stringency conditions' comprise conditions equiva
lent to binding or hybridization at 42°C. in a solution con
sisting of 5xSSPE (43.8 g/l NaCl, 6.9 g/l NaH2POHO and
1.85g/1 EDTA, pH adjusted to 7.4 with NaOH), 0.1% SDS,
5xDenhardt’s reagent 50xDenhardt’s contains per 500 ml: 5
gFicoll (Type 400, Pharamcia), 5 g BSA (Fraction V: Sigma)
and 100 ug/ml denatured salmon sperm DNA followed by
washing in a solution comprising 5xSSPE, 0.1% SDS at 42
C. when a probe of about 500 nucleotides in length is
employed.
It is well known that numerous equivalent conditions may
be employed to comprise desired stringency conditions; fac
tors such as the length and nature (DNA, RNA, base compo
sition) of the probe and nature of the target (DNA, RNA, base
composition, present in Solution or immobilized, etc.) and the
concentration of the salts and other components (e.g., the
presence or absence of formamide, dextran Sulfate, polyeth
ylene glycol) are considered and the hybridization Solution
may be varied to generate conditions of low stringency
hybridization different from, but equivalent to, the above
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listed conditions. In addition, the art knows conditions that

promote hybridization under conditions of high Stringency
(e.g., increasing the temperature of the hybridization and/or
wash steps, the use of formamide in the hybridization solu
tion, etc.).

40

When used in reference to a double-stranded nucleic acid

sequence Such as a cDNA or genomic clone, the term "sub
stantially homologous' refers to any probe that can hybridize
to either or both strands of the double-stranded nucleic acid

45

sequence under conditions of low to high Stringency as
described above.

When used in reference to a single-stranded nucleic acid
sequence, the term 'substantially homologous' refers to any
probe that can hybridize (i.e., it is the complement of) the
single-stranded nucleic acid sequence under conditions of
low to high Stringency as described above.
Amplification' is a special case of nucleic acid replication
involving template specificity. It is to be contrasted with non
specific template replication (i.e., replication that is template
dependent but not dependent on a specific template). Tem
plate specificity is here distinguished from fidelity of
replication (i.e., synthesis of the proper polynucleotide
sequence) and nucleotide (ribo- or deoxyribo-) specificity.
Template specificity is frequently described in terms of “tar
get specificity. Target sequences are “targets' in the sense
that they are sought to be sorted out from other nucleic acid.
Amplification techniques have been designed primarily for
this sorting out.
Template specificity is achieved in most amplification
techniques by the choice of enzyme. Amplification enzymes
are enzymes that, under conditions they are used, will process

50
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only specific sequences of nucleic acid in a heterogeneous
mixture of nucleic acid. For example, in the case of Q Brep
licase, MDV-1 RNA is the specific template for the replicase
(Kacian et al. (1972) Proc. Natl. Acad. Sci. USA, 69:3038).
Other nucleic acid will not be replicated by this amplification
enzyme. Similarly, in the case of T7 RNA polymerase, this
amplification enzyme has a stringent specificity for its own
promoters (Chamberlin et al. (1970) Nature, 228:227). In the
case of T4 DNA ligase, the enzyme will not ligate the two
oligonucleotides or polynucleotides, where there is a mis
match between the oligonucleotide or polynucleotide sub
strate and the template at the ligation junction (Wu and Wal
lace (1989) Genomics, 4:560). Finally, Taq and Pfu
polymerases, by virtue of their ability to function at high
temperature, are found to display high specificity for the
sequences bounded and thus defined by the primers; the high
temperature results in thermodynamic conditions that favor
primer hybridization with the target sequences and not
hybridization with non-target sequences (H. A. Erlich (ed.)
(1989) PCR Technology, Stockton Press).
The term “amplifiable nucleic acid refers to nucleic acids
that may be amplified by any amplification method. It is
contemplated that “amplifiable nucleic acid' will usually
comprise “sample template.”
The term “sample template” refers to nucleic acid originat
ing from a sample that is analyzed for the presence of “target'
(defined below). In contrast, “background template' is used
in reference to nucleic acid other than sample template that
may or may not be present in a sample. Background template
is most often inadvertent. It may be the result of carryover, or
it may be due to the presence of nucleic acid contaminants
sought to be purified away from the sample. For example,
nucleic acids from organisms other than those to be detected
may be present as background in a test sample.
The term “primer' refers to an oligonucleotide, whether
occurring naturally as in a purified restriction digest or pro
duced synthetically, which is capable of acting as a point of
initiation of synthesis when placed under conditions in which
synthesis of a primer extension product which is complemen
tary to a nucleic acid strand is induced, (i.e., in the presence of
nucleotides and an inducing agent such as DNA polymerase
and at a suitable temperature and pH). The primer is prefer
ably single stranded for maximum efficiency in amplification,
but may alternatively be double stranded. If double stranded,
the primer is first treated to separate its strands before being
used to prepare extension products. Preferably, the primer is
an oligodeoxyribonucleotide. The primer must be sufficiently
long to prime the synthesis of extension products in the pres
ence of the inducing agent. The exact lengths of the primers
will depend on many factors, including temperature, Source
of primer and the use of the method.
The term “polymerase chain reaction” (“PCR) refers to
the method of K. B. Mullis U.S. Pat. Nos. 4,683, 195, 4,683,
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202, and 4,965,188, that describe a method for increasing the
concentration of a segment of a target sequence in a mixture
of genomic DNA without cloning or purification. This pro
cess for amplifying the target sequence consists of introduc
ing a large excess of two oligonucleotide primers to the DNA
mixture containing the desired target sequence, followed by a
precise sequence of thermal cycling in the presence of a DNA
polymerase. The two primers are complementary to their
respective strands of the double stranded target sequence. To
effect amplification, the mixture is denatured and the primers
then annealed to their complementary sequences within the
target molecule. Following annealing, the primers are
extended with a polymerase so as to form a new pair of
complementary strands. The steps of denaturation, primer
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annealing, and polymerase extension can be repeated many
times (i.e., denaturation, annealing and extension constitute
one “cycle'; there can be numerous “cycles') to obtain a high
concentration of an amplified segment of the desired target
sequence. The length of the amplified segment of the desired
target sequence is determined by the relative positions of the
primers with respect to each other, and therefore, this length
is a controllable parameter. By virtue of the repeating aspect
of the process, the method is referred to as the “polymerase
chain reaction’ (hereinafter "PCR). Because the desired
amplified segments of the target sequence become the pre
dominant sequences (in terms of concentration) in the mix
ture, they are said to be “PCR amplified.”
With PCR, it is possible to amplify a single copy of a
specific target sequence in genomic DNA to a level detectable
by several different methodologies (e.g., hybridization with a
labeled probe; incorporation of biotinylated primers followed
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by avidin-enzyme conjugate detection; incorporation of P

labeled deoxynucleotide triphosphates, such as dCTP or
dATP, into the amplified segment). In addition to genomic
DNA, any oligonucleotide or polynucleotide sequence can be
amplified with the appropriate set of primer molecules. In
particular, the amplified segments created by the PCR process
itselfare, themselves, efficient templates for subsequent PCR
amplifications.
The terms “PCR product,” “PCR fragment,” and “amplifi
cation product” refer to the resultant mixture of compounds
after two or more cycles of the PCR steps of denaturation,
annealing and extension are complete. These terms encom
pass the case where there has been amplification of one or
more segments of one or more target sequences.
The term “amplification reagents' refers to those reagents
(deoxyribonucleotide triphosphates, buffer, etc.), needed for
amplification except for primers, nucleic acid template, and
the amplification enzyme. Typically, amplification reagents
along with other reaction components are placed and con
tained in a reaction vessel (test tube, microwell, etc.).
The term “reverse-transcriptase' or “RT-PCR refers to a
type of PCR where the starting material is mRNA. The start
ing mRNA is enzymatically converted to complementary
DNA or “cDNA using a reverse transcriptase enzyme. The
cDNA is then used as a “template” for a “PCR reaction.
The term “gene expression” refers to the process of con
Verting genetic information encoded in a gene into RNA (e.g.,
mRNA, rRNA, tRNA, or snRNA) through “transcription” of
the gene (i.e., via the enzymatic action of an RNA poly
merase), and into protein, through “translation” of mRNA.
Gene expression can be regulated at many stages in the pro
cess. “Up-regulation” or “activation” refers to regulation that
increases the production of gene expression products (i.e.,
RNA or protein), while “down-regulation” or “repression'
refers to regulation that decrease production. Molecules (e.g.,
transcription factors) that are involved in up-regulation or
down-regulation are often called “activators' and “repres
sors, respectively.
The terms “in operable combination”, “in operable order
and “operably linked’ refer to the linkage of nucleic acid
sequences in Such a manner that a nucleic acid molecule
capable of directing the transcription of a given gene and/or
the synthesis of a desired protein molecule is produced. The
term also refers to the linkage of amino acid sequences in Such
a manner so that a functional protein is produced.
The term “regulatory element” refers to a genetic element
that controls some aspect of the expression of nucleic acid
sequences. For example, a promoter is a regulatory element
that facilitates the initiation of transcription of an operably
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14
linked coding region. Other regulatory elements are splicing
signals, polyadenylation signals, termination signals, etc.
Transcriptional control signals in eukaryotes comprise
“promoter” and "enhancer' elements. Promoters and enhanc
ers consist of short arrays of DNA sequences that interact
specifically with cellular proteins involved in transcription
(Maniatis, et al., Science 236:1237, 1987). Promoter and
enhancer elements have been isolated from a variety of
eukaryotic sources including genes in yeast, insect, mamma
lian and plant cells. Promoter and enhancer elements have
also been isolated from viruses and analogous control ele
ments, such as promoters, are also found in prokaryotes. The
selection of a particular promoter and enhancer depends on
the cell type used to express the protein of interest. Some
eukaryotic promoters and enhancers have a broad host range
while others are functional in a limited subset of cell types
(for review, see Voss, et al., Trends Biochem. Sci., 11:287,
1986; and Maniatis, et al., supra 1987).
The terms “promoter element,” “promoter,” or “promoter
sequence' as used herein, refer to a DNA sequence that is
located at the 5' end (i.e. precedes) the protein coding region
of a DNA polymer. The location of most promoters known in
nature precedes the transcribed region. The promoter func
tions as a Switch, activating the expression of a gene. If the
gene is activated, it is said to be transcribed, or participating in
transcription. Transcription involves the synthesis of mRNA
from the gene. The promoter, therefore, serves as a transcrip
tional regulatory element and also provides a site for initiation
of transcription of the gene into mRNA.
Promoters may be tissue specific or cell specific. The term
“tissue specific' as it applies to a promoter refers to a pro
moter that is capable of directing selective expression of a
nucleotide sequence of interest to a specific type of tissue
(e.g., seed tissue) in the relative absence of expression of the
same nucleotide sequence of interest in a different type of
tissue (e.g., leave tissue). Tissue specificity of a promoter may
be evaluated by, for example, operably linking a reporter gene
to the promoter sequence to generate a reporter construct,
introducing the reporter construct into the genome of a plant
Such that the reporter construct is integrated into every tissue
of the resulting transgenic plant, and detecting the expression
of the reporter gene (e.g., detecting mRNA, protein, or the
activity of a protein encoded by the reporter gene) in different
tissues of the transgenic plant. The detection of a greater level
of expression of the reporter gene in one or more tissues
relative to the level of expression of the reporter gene in other
tissues shows that the promoter is specific for the tissues in
which greater levels of expression are detected. The term
“cell type specific' as applied to a promoter refers to a pro
moter which is capable of directing selective expression of a
nucleotide sequence of interest in a specific type of cell in the
relative absence of expression of the same nucleotide
sequence of interest in a different type of cell within the same
tissue. The term “cell type specific' when applied to a pro
moter also means a promoter capable of promoting selective
expression of a nucleotide sequence of interest in a region
within a single tissue. Cell type specificity of a promoter may
be assessed using methods well known in the art, e.g., immu
nohistochemical staining. Briefly, tissue sections are embed
ded in paraffin, and paraffin sections are reacted with a pri
mary antibody that is specific for the polypeptide product
encoded by the nucleotide sequence of interest whose expres
sion is controlled by the promoter. A labeled (e.g., peroxidase
conjugated) secondary antibody that is specific for the pri
mary antibody is allowed to bind to the sectioned tissue and
specific binding detected (e.g., with avidin/biotin) by micros
copy.
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Promoters may be constitutive or regulatable. The term
“constitutive' when made in reference to a promoter means
that the promoter is capable of directing transcription of an
operably linked nucleic acid sequence in the absence of a
stimulus (e.g., heat shock, chemicals, light, etc.). Typically,
constitutive promoters are capable of directing expression of
a transgene in Substantially any cell and any tissue. Exem
plary constitutive plant promoters include, but are not limited
to SD Cauliflower Mosaic Virus (CaMV SD; see e.g., U.S.
Pat. No. 5,352.605, incorporated herein by reference), man
nopine synthase, octopine synthase (ocs), Superpromoter (see
e.g., WO 95/14098), and ubi3 (see e.g., Garbarino and
Belknap (1994) Plant Mol. Biol. 24:119-127) promoters.
Such promoters have been used successfully to direct the
expression of heterologous nucleic acid sequences in trans
formed plant tissue.
In contrast, a “regulatable' promoter is one which is
capable of directing a level of transcription of an operably
linked nuclei acid sequence in the presence of a stimulus (e.g.,
heat shock, chemicals, light, etc.) which is different from the
level of transcription of the operably linked nucleic acid
sequence in the absence of the stimulus.
The enhancer and/or promoter may be “endogenous” or
“exogenous” or "heterologous.” An "endogenous enhancer
or promoter is one that is naturally linked with a given gene in
the genome. An "exogenous” or "heterologous' enhancer or
promoter is one that is placed in juxtaposition to a gene by
means of genetic manipulation (i.e., molecular biological
techniques) Such that transcription of the gene is directed by
the linked enhancer or promoter. For example, an endogenous
promoter in operable combination with a first gene can be
isolated, removed, and placed in operable combination with a
second gene, thereby making it a "heterologous promoter” in
operable combination with the second gene. A variety of such
combinations are contemplated (e.g., the first and second
genes can be from the same species, or from different species.
The presence of “splicing signals' on an expression vector
often results in higher levels of expression of the recombinant
transcript in eukaryotic host cells. Splicing signals mediate
the removal of introns from the primary RNA transcript and
consist of a splice donor and acceptor site (Sambrook, et al.
(1989) Molecular Cloning: A Laboratory Manual, 2nd ed.,
Cold Spring Harbor Laboratory Press, New York, pp. 16.716.8). A commonly used splice donor and acceptor site is the
splice junction from the 16S RNA of SV40.
Efficient expression of recombinant DNA sequences in
eukaryotic cells requires expression of signals directing the
efficient termination and polyadenylation of the resulting
transcript. Transcription termination signals are generally
found downstream of the polyadenylation signal and area few
hundred nucleotides in length. The term “poly(A) site' or
"poly(A) sequence' as used herein denotes a DNA sequence
which directs both the termination and polyadenylation of the
nascent RNA transcript. Efficient polyadenylation of the
recombinant transcript is desirable, as transcripts lacking a
poly(A)tail are unstable and are rapidly degraded. The poly
(A) signal utilized in an expression vector may be "heterolo
gous' or "endogenous.” An endogenous poly(A) signal is one
that is found naturally at the 3' end of the coding region of a
given gene in the genome. A heterologous poly(A) signal is
one which has been isolated from one gene and positioned 3'
to another gene. A commonly used heterologous poly(A)
signal is the SV40 poly(A) signal. The SV40 poly(A) signal is
contained on a 237 bp BamHI/BclI restriction fragment and
directs both termination and polyadenylation (Sambrook,
supra, at 16.6-16.7).
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The term “selectable marker” refers to a gene which
encodes an enzyme having an activity that confers resistance
to an antibiotic or drug upon the cell in which the selectable
marker is expressed, or which confers expression of a trait
which can be detected (e.g., luminescence or fluorescence).
Selectable markers may be “positive' or “negative.”
Examples of positive selectable markers include the neomy
cin phosphotransferase (NPTII) gene which confers resis
tance to G418 and to kanamycin, and the bacterial hygromy
cin phosphotransferase gene (hyg), which confers resistance
to the antibiotic hygromycin. Negative selectable markers
encode an enzymatic activity whose expression is cytotoxic
to the cell when grown in an appropriate selective medium.
For example, the HSV-tkgene is commonly used as a negative
selectable marker. Expression of the HSV-tk gene in cells
grown in the presence of gancyclovir or acyclovir is cyto
toxic; thus, growth of cells in selective medium containing
gancyclovir or acyclovir selects against cells capable of
expressing a functional HSVTK enzyme.
The term “vector refers to nucleic acid molecules that
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transfer DNA segment(s) from one cell to another. The term
“vehicle' is sometimes used interchangeably with “vector.”
The terms “expression vector” or “expression cassette'
refer to a recombinant DNA molecule containing a desired
coding sequence and appropriate nucleic acid sequences nec
essary for the expression of the operably linked coding
sequence in a particular host organism. Nucleic acid
sequences necessary for expression in prokaryotes usually
include a promoter, an operator (optional), and a ribosome
binding site, often along with other sequences. Eukaryotic
cells are known to utilize promoters, enhancers, and termina
tion and polyadenylation signals.
The terms “transfection', “transformation', “transfected
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and “transformed are used interchangeably and refer to the
introduction of foreign DNA into cells. Transfection may be
accomplished by a variety of means known to the art includ
ing calcium phosphate-DNA co-precipitation, DEAE-dext
ran-mediated transfection, polybrene-mediated transfection,
glass beads, electroporation, microinjection, liposome
fusion, lipofection, protoplast fusion, viral infection, biolis
tics (i.e., particle bombardment) and the like.
The terms “infecting and “infection' when used with a
bacterium refer to co-incubation of a target biological sample,
(e.g., cell, tissue, etc.) with the bacterium under conditions
Such that nucleic acid sequences contained within the bacte
rium are introduced into one or more cells of the target bio
logical sample.
The term 'Agrobacterium” refers to a soil-borne, Gram
negative, rod-shaped phytopathogenic bacterium which
causes crown gall. The term "Agrobacterium' includes, but is
not limited to, the strains Agrobacterium tumefaciens, (which
typically causes crown gall in infected plants), and Agrobac
terium rhizogens (which causes hairy root disease in infected
host plants). Infection of a plant cell with Agrobacterium
generally results in the production of opines (e.g., nopaline,
agropine, octopine etc.) by the infected cell. Thus, Agrobac
terium strains which cause production of nopaline (e.g., Strain
LBA4301, C58, A208, GV3101) are referred to as “nopaline
type Agrobacteria; Agrobacterium strains which cause pro
duction of octopine (e.g., strain LBA4404, Achs, B6) are
referred to as "octopine-type Agrobacteria; and Agrobacte
rium strains which cause production of agropine (e.g., Strain
EHA105, EHA101, A281) are referred to as “agropine-type”
Agrobacteria.
The terms “bombarding, “bombardment,” and “biolistic
bombardment” refer to the process of accelerating particles
towards a target biological sample (e.g., cell, tissue, etc.) to
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effect wounding of the cell membrane of a cell in the target
biological sample and/or entry of the particles into the target
biological sample. Methods for biolistic bombardment are
known in the art (e.g., U.S. Pat. No. 5,584.807, the contents of
which are incorporated herein by reference), and are com
mercially available (e.g., the helium gas-driven microprojec
tile accelerator (PDS-1000/He, BioRad).
The term “microwounding” when made in reference to
plant tissue refers to the introduction of microscopic wounds
in that tissue. Microwounding may be achieved by, for
example, particle bombardment as described herein.
The term “transgenic’ when used in reference to a plant or
fruit or seed (i.e., a “transgenic plant’ or “transgenic fruit' or
a “transgenic seed') refers to a plant or fruit or seed that
contains at least one heterologous gene in one or more of its
cells. The term “transgenic plant material refers broadly to a
plant, a plant structure, a plant tissue, a plant seed or a plant
cell that contains at least one heterologous gene in one or
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binant nucleic acid molecule.

The term "isolated when used in relation to a nucleic acid,
25

formed cell are included in the definition of transformants.

The term “wild-type' when made in reference to a gene
refers to a gene that has the characteristics of a gene isolated
from a naturally occurring source. The term “wild-type'
when made in reference to a gene product refers to a gene
product that has the characteristics of a gene product isolated
from a naturally occurring source. A wild-type gene is that
which is most frequently observed in a population and is thus
arbitrarily designated the “normal” or “wild-type' form of the
gene. In contrast, the term “modified’ or “mutant when
made in reference to a gene or to a gene product refers,
respectively, to a gene or to a gene product which displays
modifications in sequence and/or functional properties (i.e.,
altered characteristics) when compared to the wild-type gene
or gene product. It is noted that naturally-occurring mutants
can be isolated; these are identified by the fact that they have
altered characteristics when compared to the wild-type gene
or gene product.
The term “antisense' refers to a deoxyribonucleotide
sequence whose sequence of deoxyribonucleotide residues is
in reverse 5' to 3' orientation in relation to the sequence of
deoxyribonucleotide residues in a sense strand of a DNA
duplex. A “sense strand of a DNA duplex refers to a strand in
a DNA duplex that is transcribed by a cell in its natural state
into a “sense mRNA. Thus an “antisense” sequence is a
sequence having the same sequence as the non-coding strand
in a DNA duplex. The term “antisense RNA” refers to a RNA
transcript that is complementary to all or part of a target
primary transcript or mRNA and that blocks the expression of
a target gene by interfering with the processing, transport
and/or translation of its primary transcript or mRNA. The
complementarity of an antisense RNA may be with any part
of the specific gene transcript, i.e., at the 5' non-coding
sequence, 3' non-coding sequence, introns, or the coding
sequence. In addition, as used herein, antisense RNA may
contain regions of ribozyme sequences that increase the effi
cacy of antisense RNA to block gene expression. “Ribozyme’
refers to a catalytic RNA and includes sequence-specific
endoribonucleases. “Antisense inhibition” refers to the pro
duction of antisense RNA transcripts capable of preventing
the expression of the target protein.

The term “recombinant' when made in reference to a
nucleic acid molecule refers to a nucleic acid molecule that is

comprised of segments of nucleic acid joined together by
means of molecular biological techniques. The term “recom
binant when made in reference to a protein or a polypeptide
refers to a protein molecule that is expressed using a recom

more of its cells.
The terms “transformants' or “transformed cells' include

the primary transformed cell and cultures derived from that
cell without regard to the number of transfers. All progeny
may not be precisely identical in DNA content, due to delib
erate or inadvertent mutations. Mutant progeny that have the
same functionality as screened for in the originally trans
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The term “posttranscriptional gene silencing or “PTGS’
refers to silencing of gene expression in plants after transcrip
tion, and appears to involve the specific degradation of
mRNAS Synthesized from gene repeats.
The term “overexpression” refers to the production of a
gene product in transgenic organisms that exceeds levels of
production in normal or non-transformed organisms. The
term "cosuppression” refers to the expression of a foreign
gene that has substantial homology to an endogenous gene
resulting in the Suppression of expression of both the foreign
and the endogenous gene. The term “altered levels' refers to
the production of gene product(s) in transgenic organisms in
amounts or proportions that differ from that of normal or
non-transformed organisms.

as in “an isolated oligonucleotide' refers to a nucleic acid
sequence that is identified and separated from at least one
contaminant nucleic acid with which it is ordinarily associ
ated in its natural source. Isolated nucleic acid is present in a
form or setting that is different from that in which it is found
in nature.
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The term “purified’ refers to molecules, either nucleic or
amino acid sequences, that are removed from their natural
environment, isolated or separated. An "isolated nucleic acid
sequence' is therefore a purified nucleic acid sequence. "Sub
stantially purified molecules are at least 60% free, preferably
at least 75% free, and more preferably at least 90% free from
other components with which they are naturally associated.
The term “purified’ or “to purify also refer to the removal of
contaminants from a sample. The removal of contaminating
proteins results in an increase in the percent of polypeptide of
interest in the sample. In another example, recombinant
polypeptides are expressed in plant, bacterial, yeast, or mam
malian host cells and the polypeptides are purified by the
removal of host cell proteins; the percent of recombinant
polypeptides is thereby increased in the sample.
The term “sample' is used in its broadest sense. In one
sense it can refer to a plant cell or tissue. In another sense, it
is meant to include a specimen or culture obtained from any
Source, as well as biological and environmental samples.
Biological samples may be obtained from plants or animals
(including humans) and encompass fluids, Solids, tissues, and
gases. Environmental samples include environmental mate
rial Such as Surface matter, soil, water, and industrial samples.
These examples are not to be construed as limiting the sample
types applicable to the present invention.
DESCRIPTION OF THE INVENTION

The present invention relates to compositions and methods
for controlling nematode infestation of plants or animals. In
particular, the present invention provides vectors comprising
sequences designed to control nematodes by RNA interfer
ence (RNAi) and transgenic plants transformed with Such
vectors. The compositions and methods of the present inven
tion can be used to inhibit the growth and reproduction of a
number of nematodes species, including, but not limited to
plant parasitic nematodes and nematodes in the following
genera: Acontylus, Criconemella, Pseudhalenchus, Afenes
trata, Cucullity lenchus, Lelenchus, Psilenchus, Aglenchus,
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Cryphodera, Pterotylenchus, Allotylenchus, Cynipanguina,
Macrotrophurus, Punctodera, Amplimerlinius, Malenchus,
Anguina, Discocriconemella, Meloidodera, Radopholus,
Antarctenchus, Dity lenchus, Meloidoderita, Rhizonema, Ant
arctylus, Dolichodera, Meloidogyne, Rotylenchulus, Aorolai
mus, Dolichodorus, Meloinema, Rotylenchus, Aphasmaty
lenchus, Duotylenchus, Merlinius, Apratylenchoides,
Miculenchus, Sarisodera, Atalodera, Ecphy adophora,
Mitranema, Sauerty lenchus, Atetvlenchus, Ecphy adophoroi
des, Morulaimus, Scutellonema, Atylenchus, Epicharinema,
Mukazia, Senegalonema, Euty lenchus, Sphaeronema, Bake
mema, Nacobbodera, Subanguina, Basiria, Filenchus,
Nacobbus, Sychnotylenchus, Basirienchus, Nagelus, Basiroi

20
endonuclease, and probably serve as a discriminator to select
mRNAs. Once selected, mRNAs are cleaved at sites 21 to 23

nucleotides apart.
In preferred embodiments, the dsRNA used to initiate
RNAi may be isolated from native source or produced by
known means, e.g., transcribed from DNA. The promoters
and vectors described in more detail below are suitable for
10

des, Bellodera, Geocenamus, Neodolichodorus, Thada,

Belonolaimus, Globodera, Neopsilenchus, Theca vermicula
tus, Blandicephalanema, Graciliacus, Neothada, Trichotylen
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chus, Boleodorus, Graciliancea, Nothocriconenoides, Triv

ersus, Brachydorus, Trophonema, Bursadera, Halenchus,
Ogma, Trophotylenchulus, Helicotylenchus, Paraphelen
chus, Trophurus, Cacopaurus, Hemicriconenoides, Pararo
tylenchus, Tvlenchocriconema, Cactodera, Hemicyclio
phora, Paratrophurus, Tvlenchorhynchus, Caloosia,
Heterodera, Paratylenchus, Tilenchulus, Cambellenchus,
Hirschmanniella, Pateracephalanema, Tilenchus, Car
phodorus, Hoplolaimus, Pleurotylenchus, Tvlodorus, Ceph
alenchus, Hoplotylus, Polenchus, Clavilenchus, Coslenchus,
Hylonema, Pratylenchoides, Verutus, Criconema, Pratylen
chus, Zygotylenchus; and animal parasitic nematodes of the
following genera: Trichuris, Acylostoma, Necator, Strongy
loides, Toxocara, Baylisacaris, Trichinella, Draccunculus,
Filarioidea, Onchocerca, Loa, Dirofilaria, and Anisakis.
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I. RNAi

RNAi refers to the introduction of homologous double
stranded RNA (dsRNA) to target a specific gene product,
resulting in post transcriptional silencing of that gene. This
phenomena was first reported in Caenorhabditis elegans by
Guo and Kemphues (Par-1, A gene required for establishing
polarity in C. elegans embryos, encodes a putative Ser/Thr
kinase that is asymmetrically distributed, 1995, Cell, 81 (4)
611-620) and subsequently Fire et al. (Potent and specific
genetic interference by double-stranded RNA in Caenorhab
ditis elegans, 1998, Nature 391:806-811) discovered that it is
the presence of dsRNA, formed from the annealing of sense
and antisense Strands present in the in vitro RNA preps, that is
responsible for producing the interfering activity.
The present invention contemplates the use of RNA inter
ference (RNAi) to downregulate the expression of genes
needed for nematode viability and reproduction, thus reduc
ing nematode infestation of plants. In both plants and ani
mals, RNAi is mediated by RNA-induced silencing complex
(RISC), a sequence-specific, multicomponent nuclease that
destroys messenger RNAS homologous to the silencing trig
ger. RISC is known to contain short RNAs (approximately 22
nucleotides) derived from the double-stranded RNA trigger,
although the protein components of this activity are
unknown. However, the 22-nucleotide RNA sequences are
homologous to the target gene that is being Suppressed. Thus,
the 22-nucleotide sequences appear to serve as guide
sequences to instruct a multicomponent nuclease, RISC, to
destroy the specific mRNAs.
Carthew has reported (Curr. Opin. Cell Biol. 13(2):244
248 (2001) that eukaryotes silence gene expression in the
presence of dsRNA homologous to the silenced gene. Bio
chemical reactions that recapitulate this phenomenon gener
ate RNA fragments of 21 to 23 nucleotides from the double
stranded RNA. These stably associate with an RNA

producing dsRNA. RNA is synthesized either in vivo or in
vitro. In some embodiments, endogenous RNA polymerase
of the cell may mediate transcription in vivo, or cloned RNA
polymerase can be used for transcription in vivo or in vitro. In
other embodiments, the RNA is provided transcription from a
transgene in Vivo oran expression construct. In some embodi
ments, the RNA strands are polyadenylated; in other embodi
ments, the RNA strands are capable of being translated into a
polypeptide by a cells translational apparatus. In still other
embodiments, the RNA is chemically or enzymatically syn
thesized by manual or automated reactions. In further
embodiments, the RNA is synthesized by a cellular RNA
polymerase or a bacteriophage RNA polymerase (e.g., T3,
T7, SP6). If synthesized chemically or by in vitro enzymatic
synthesis, the RNA may be purified prior to introduction into
the cell. For example, RNA can be purified from a mixture by
extraction with a solvent or resin, precipitation, electrophore
sis, chromatography, or a combination thereof. Alternatively,
the RNA may be used with no or a minimum of purification to
avoid losses due to sample processing. In some embodiments,
the RNA is dried for storage or dissolved in an aqueous
solution. In other embodiments, the solution contains buffers

or salts to promote annealing, and/or stabilization of the
duplex strands.
In some embodiments, the dsRNA is transcribed from the
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vectors as two separate stands. In other embodiments, the two
strands of DNA used to form the dsRNA may belong to the
same or two different duplexes in which they each form with
a DNA strand of at least partially complementary sequence.
When the dsRNA is thus-produced, the DNA sequence to be
transcribed is flanked by two promoters, one controlling the
transcription of one of the strands, and the other that of the
complementary Strand. These two promoters may be identical
or different. In some embodiments, a DNA duplex provided at
each end with a promoter sequence can directly generate
RNAs of defined length, and which can join in pairs to form
a dsRNA. See, e.g., U.S. Pat. No. 5,795,715, incorporated
herein by reference. RNA duplex formation may be initiated
either inside or outside the cell.
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Inhibition is sequence-specific in that nucleotide
sequences corresponding to the duplex region of the RNA are
targeted for genetic inhibition. RNA molecules containing a
nucleotide sequence identical to a portion of the target gene
are preferred for inhibition. RNA sequences with insertions,
deletions, and single point mutations relative to the target
sequence have also been found to be effective for inhibition.
Thus, sequence identity may optimized by sequence com
parison and alignment algorithms known in the art (see Grib
skov and Devereux, Sequence Analysis Primer, Stockton
Press, 1991, and references cited therein) and calculating the
percent difference between the nucleotide sequences by, for
example, the Smith-Waterman algorithm as implemented in
the BESTFIT software program using default parameters
(e.g., University of Wisconsin Genetic Computing Group).
Greater than 90% sequence identity, or even 100% sequence
identity, between the inhibitory RNA and the portion of the
target gene is preferred. Alternatively, the duplex region of the
RNA may be defined functionally as a nucleotide sequence
that is capable of hybridizing with a portion of the target gene
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transcript. The length of the identical nucleotide sequences
may be at least 25, 50, 100, 200, 300 or 400 bases.
There is no upper limit on the length of the dsRNA that can
be used. For example, the dsRNA can range from about 21
base pairs (bp) of the gene to the full length of the gene or

5

more. In one embodiment, the dsRNA used in the methods of

the present invention is about 1000 bp in length. In another
embodiment, the dsRNA is about 500 bp in length. In yet
another embodiment, the dsRNA is about 22 bp in length. In
Some preferred embodiments, the sequences that mediate
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RNAi are from about 21 to about 23 nucleotides. That is, the

isolated RNAs of the present invention mediate degradation
of the target RNA (e.g., major sperm protein, chitin synthase,
or RNA polymerase II).
The double stranded RNA of the present invention need
only be sufficiently similar to natural RNA that it has the
ability to mediate RNAi for the target RNA. In one embodi
ment, the present invention relates to RNA molecules of
varying lengths that direct cleavage of specific mRNA to
which their sequence corresponds. It is not necessary that
there be perfect correspondence of the sequences, but the
correspondence must be sufficient to enable the RNA to direct
RNAi cleavage of the target mRNA. In a particular embodi
ment, the RNA molecules of the present invention comprise a
3' hydroxyl group. In some embodiments, the amount of
target RNA (mRNA) is reduced in the cells of the target
organism (e.g., H. glycines) exposed to target specific double
Stranded RNA as compared to target organisms that have not
been exposed to target specific double stranded RNA.
Accordingly, in Some embodiments, the present invention
provides isolated RNA molecules (double-stranded or single
stranded) that are complementary to sequences required for
nematode viability and/or reproduction. In some embodi
ments, the RNA molecules utilized mediate RNAi for embry
onic lethal and sterile genes. Many genes with sterile or
embryonic lethal RNAi phenotypes have been identified in
high throughput screens (Fraser, A. G. Kamath, R. S. Zip
perlen, P., Martinez-Campos, M., Sohrmann, M. and Ahr
inger, J. (2000). Functional genomic analysis of C. elegans
chromosome I by systematic RNA interference. Nature 408,
325-330; Gonczy, P. Echeverri, G., Oegema, K., Coulson, A.,
Jones, S.J., Copley, R. R., Duperon, J. Oegema, J., Brehm,
M. Cassin, E. et al. (2000). Functional genomic analysis of
cell division in C. elegans using RNAi of genes on chromo
some III. Nature 408,331-336; Maeda, I., Kohara, Y., Yama

moto, M. and Sugimoto, A. (2001). Large-scale analysis of
gene function in Caenorhabditis elegans by high-throughput
RNAi. Curr Biol 11, 171-176). Much of this data and all of the
sequences are available through WormBase (wormbase.org/).
To date, over 2033 genes have been found to have an embry
onic lethal RNAi phenotype and over 573 have a sterile RNAi
phenotype. As described in more detail below and in the
examples, these sequences may be screened for oral activity
when expressed in plant tissue. In other embodiments, genes
from this group that are specific to nematodes are utilized for
RNAi so as to minimize interactions against endogenous
proteins of plants, livestock and humans.
In some embodiments, probes that are specific for a nema
tode gene of interest are amplified from a DNA sample pre
pared from C. elegans by using primers designed from C.
elegans genomic DNA or cDNA. Genes amplified from C.
elegans DNA are then used as probes for homologous genes
from a genomic or cDNA libraries prepared from the nema
tode of interest (e.g., H. glycines). In other embodiments,
degenerate primers based on the C. elegans sequences are
utilized to amplify the gene of interest from a library derived
from the nematode of interest. These genes are then inserted
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into an expression vector so that a nematode double stranded
RNA corresponding to the gene of interest is produced when
the vector is used to transfect a plant.
Accordingly, in Some embodiments, the present invention
utilizes RNAi genes encoding dsRNA sequences that target
nematode genes identified as having embryonic lethal or ster
ile RNAi phenotypes as identified by feeding nematodes
dsRNA. The coding sequences for the target RNAs are avail
able in public databases, including Wormbase (wormbase
.org). In still further embodiments, the genes utilized for
RNAi are selected from the group consisting of major sperm
protein, chitin synthase, and RNA polymerase II. The meth
ods and compositions of the present invention have been
exemplified for the control of H. glycines. However, it will be
recognized that these materials and methods can be used the
control of other nematodes. Accordingly the present inven
tion provides the sequences for H. glycines major sperm
protein (e.g., SEQ ID NO:1), chitin synthase (e.g., SEQ ID
NO:18), and RNA polymerase II (e.g., SEQ ID NO:9). As
described above, the entire coding sequence of the genes can
be used to make dsRNA for RNAi, or, alternatively, subse
quences can be utilized. The following table presents other
suitable subsequences for use in RNAi. Both these sequences
and their complements are expressed from vectors as
described herein to form double stranded RNA molecules.
TABLE 1.

30

Sequences for RNAi
Major sperm protein subsequences
35

SEQ ID NO: 25 CGGGGTCGAAGGCGTCNCAGAANACGGCCAC
GTTGACAGATTCCTTTGGGCCGANCACTCCG

SEQ ID NO: 26 TCCGGCGGGTTCATGTTGATNCGCTTCGGTTTG
SEQ ID NO: 27 CGTGGTGTCGGCTGGGTCCGGTGT
GTTGGTCCACTCCGC

SEQ ID NO:28 GGCACGTTGGTCCACGCCACG
GTCACACGGTCGTCCTTGGTGTCCTCGCTGC

40 SEQ ID NO: 29 GGCGTCNCAGAANACGGCCAC
GTTGACAGATTCCTTTGGGCCGANCACTCCG

SEQ ID NO:30 GGGCGGTTCCGGCACGTTGGTCCACGCCACG
GTCACACGGTCGTCCTTGGTGTCCTCGCTGC

RNA polymerase II subsequences
45

SEO ID NO:31 AATCTGTCAACGTGGCCGTNTTCTGNGACGCC

50

SEQ ID NO:32

SEQ ID NO:33
55

SEQ ID NO:34
SEO ID NO:35
60

SEQ ID NO:36
SEO ID NO:37
65

TTCGACCCCGGCAGCGAGGACACCAAGGACGA
CCGTGTGACCGTGGCGTGGACCAACGTGCCGG
AACCGCCCGGCGCCGCCGCCGCCGCGGAGTGG
ACCAACACACCGGACCCAGCCGACACCACGTT
CAAG
GGTCGTCCTTGGTGTCCTCGCTGCCGGGGTCGA
AGGCGTCNCAGAANACGGCCACGTTGACAGATT
CCTTTGGGCCGANCACTCCGTCCGGCGGGTTCA
TGTTGATNCGCTTCGGTTTG
TTGAACGTGGTGTCGGCTGGGTCCGGTGTGTT
GGTCCACTCCGCGGCGGCGGCGGCGCCGGGCG
GTTCCGGCACGTTGGTCCACGCCACGGTCACAC
GGTCGTCCTTGGTGTCCTCGCTGCCGGGGTCGA
GGTCGTCCTTGGTGTCCTCGCTGCCGGGGTCGA
AGGCGTCNCAGAANACGGCCACGTTGACAGATT
TTCAAGACCACCAAACCGAAGCGNATCAACAT
GAACCCGCCGGACGGAGTGNTCGGCCCAAAGG
AATCTGTCAACGTGGCCGTNTTCTGNGACGCC
TTCGACCCCGGCAGCGAGGACACCAAGGACGA
CCGTGTGACCGTGGCGTGGACCAACGTGCCGG
AACCGCCCGGCGCCGCCGCCGCCGCGGAGTGG
ACCAACACACCGGACCCAGCCGACACCACGTT
ATCATGTCCATGTTGAGGTGACGAAGCATCCTTCCAT
CAGACGTTGTACTCGATCGGCAAGTTCTTGCGGC
GCACCATCCCGTCTCCCTGGAACCA
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TABLE 1 - continued

TABLE 2-continued

Sequences for RNAi

Gene(s)

Feeding phenotype

dnc-1

Mt

Chitin synthase sequences
bir-1

Mt

pal-1

CCATTGGTTCCAAAAG

Mt

SEO ID NO:39 GCTGCTGAGCATGTGTTCGGCTGTGTTTTGTGTGC
10

SEO ID NO: 40 TCTGTTTCGTGCTTCTGCTCTCATGGATGACAATGT
GATGCACAAATACA

SEO ID NO: 41 CCAAAANTGCCTCCGAACCNACGACNATTTTGTTC
SEO ID NO: 42
SEO ID NO: 43
SEO ID NO: 44

AGTATGATCAAGGCGAAGACCCGATGGA
TCTGTTTCGTGCTTCTGCTCTCATGGATGACAATGT
GATGCACAAATACACCAAAANTGCCTCCGAACCN
ACGACNATTTTGTTCAGTATGATCAAGGCG
TCTGTTTCGTGCTTCTGCTCTCATGGATGACAATGT
GATGCACAAATACACCAAAANTGCCTCCGAACCNA
CGACNATTTTGTTCAGTATGATCAAGGCG
TCTGTTTCGTGCTTCTGCTCTCATGGATGACAATGTG
ATGCACAAATACACCAAA.

Additionally, homologous sequences from other nema
todes may be utilized for targeting the corresponding species
of nematode. For example, a number of homologous Major
sperm protein genes are known, including those identified by
the following GenBank Accession numbers: GI403083,

15

inhibitor of apoptosis

protein (IAP) homologue
required to specify the
Somatic identity of one
posterior blastomere in the
4 cell embryo

dif-1

Mt

plk-1

Mt

Mitochondrial Transporters
Polo-like kinase PLK-1 is

dhc-1

Mtl, Emb

required for nuclear
envelope breakdown and
the completion of meiosis
Dynein Heavy Chain

mex-3

Mt

regulates blastomere

identity
Bmd, body morphology defect; Clr, clear; Emb, embryonic lethal; Gro, slow growth; Him,
high incidence ofmales;Lwl, larvallethal (death at any larval stage); Milt, molting defect (old
cuticle remains attached); Prz, paralyzed; Pwl, protruding vulva; Ste, sterile; Unc, uncoor
dinated; Mtl, maternal lethal.

25

GI403087, GI17535306, GI159665, GI1373354,
GI1373307, GI159897, GI12055908, and GI12055882

among others. Such sequences can be conveniently identified
by conducting BLASTN of BLASTP searches of GenBank as
appropriate.
Other genes that are useful for targeting include those
described in Kamath et al., Effectiveness of specific RNA
mediated interference through ingested double-stranded
RNA in Caenorhabditis elegans. Genome Biology, 201):re
search0002.1-0002.10 (2000). These genes are identified in
the following Table:

required for mitotic spindle
orientation

SEO ID NO:38 TGGTTTGGTACCAAAAGTTCGAGTACGCAATCGC
CCCCGGTAGCTTCTC

Gene information
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II. Transgenic Plants
In some embodiments, the present invention provides
transgenic plants that express dsRNA molecules that corre
spond to target molecules in desired nematode species. It is
contemplated that nematodes feeding on the transgenic plants
ingest the dsRNA molecules, which in turn decrease the abun
dance of target RNA within the nematode species. By target
ing genes that are required for fertility or fitness of the nema
tode, nematode growth and reproduction is reduced thus
reducing nematode induced plant damage (e.g., root cysts).
A heterologous gene encoding a RNAi gene of the present
invention, which includes variants of the RNAi gene, includes
any suitable sequence that encodes an double stranded mol
ecule specific for a nematode target RNA. Preferably, the
heterologous gene is provided within an expression vector
Such that transformation with the vector results in expression
of the double stranded RNA molecule; suitable vectors are

TABLE 2
Gene(s)

Feeding phenotype

KO4G2.8a.
Unc, Bmd, Lvl
F18C12.2a. Emb, Unc, Mlt, Bmd
ZK265.5, 6* Gro

40

Gene information

apr-1 (APC-related)
DNA-J domain
G-protein-coupled

receptorfunknown function
TO1 G9.4
TO1 G9.5
TO1 G9.6a
F52B5.6

Emb, Gro, Clr
Emb
Emb, Gro, Pvl
Emb, Ste

kup-2 (unknown function)
mei-1 (meiotic spindle formation)
kin-10 (CKII-beta subunit)
Ribosomal protein L25

T19A6.2a.
D1081.2
D1081.8

Gro
Unc, Prz
Emb

Ynr053p-like protein
MADS domain
Myb-like DNA-binding

45

50

domain

KO2B12.1

Unc, Mlt

KO2B12.3

Ste, Gro

WD domains

ceh-6 (POU homeodomain

protein)

KO2B12.8

Him

Unknown function

Gpb-1
gpb-1

Mt.

Identity of corresponding
gene under review

bar-1

Mt.
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required for establishing

polarity
bar-2

Mt.

par-3

Mt.

required for blastomere
asymmetry
control of cleavage spindle

par-6

Mt.

orientation
involved in the

cyk-1
skin-1

Mt.
Mt.
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spindle orientation

In yet other embodiments of the present invention, a trans
genic plant comprises a heterologous gene encoding a RNAi
gene of the present invention operably linked to an inducible
promoter, and is grown either in the presence of the an induc
ing agent, or is grown and then exposed to an inducing agent.
In still other embodiments of the present invention, a trans
genic plant comprises a heterologous gene encoding a RNAi
gene of the present invention operably linked to a promoter
which is either tissue specific or developmentally specific,
and is grown to the point at which the tissue is developed or
the developmental stage at which the developmentally-spe
cific promoter is activated. Such promoters include seed and
root specific promoters. In still other embodiments of the
present invention, the transgenic plant comprises a RNAi
gene of the present invention operably linked to constitutive
promoter. In further embodiments, the transgenic plants of
the present invention express at least one double stranded
RNA molecule at a level sufficient to reduce the proliferation
of nematodes as compared to the proliferation of nematodes
observed in a nontransgenic plant.
1. Plants

establishment of asymmetry
required for cytokinesis
required for mitotic

described below.

65

The methods of the present invention are not limited to any
particular plant. Indeed, a variety of plants are contemplated,
including but not limited to soybean, wheat, oats, milo, Sor
ghum, cotton, tomato, potato, tobacco, pepper, rice, corn,
barley, Brassica, Arabidopsis, Sunflower, poplar, pineapple,
banana, turfgrass, and pine. Many commercial cultivars can
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be transformed with heterologous genes. In cases where that
is not possible, non-commercial cultivars of plants can be
transformed, and the trait for expression of the RNAi gene of
the present invention moved to commercial cultivars by
breeding techniques well-known in the art.

5

2. Vectors

The methods of the present invention contemplate the use
of at least one heterologous gene encoding a RNAi gene of the
present invention. Heterologous genes intended for expres
sion in plants are first assembled in expression cassettes com
prising a promoter. Methods which are well known to those
skilled in the art may be used to construct expression vectors
containing a heterologous gene and appropriate transcrip

10

tional and translational control elements. These methods

include invitro recombinant DNA techniques, synthetic tech
niques, and in vivo genetic recombination. Such techniques
are widely described in the art (See e.g., Sambrook. et al.
(1989) Molecular Cloning, A Laboratory Manual, Cold
Spring Harbor Press, Plainview, N.Y., and Ausubel, F. M. et
al. (1989) Current Protocols in Molecular Biology, John
Wiley & Sons, New York, N.Y).
In general, these vectors comprise a nucleic acid sequence
of the invention encoding a RNAi gene of the present inven
tion (as described above) operably linked to a promoter and
other regulatory sequences (e.g., enhancers, polyadenylation
signals, etc.) required for expression in a plant.
Promoters include but are not limited to constitutive pro
moters, tissue-, organ-, and developmentally-specific pro
moters, and inducible promoters. Examples of promoters
include but are not limited to: constitutive promoter 35S of
cauliflower mosaic virus; a wound-inducible promoter from
tomato, leucine amino peptidase (“LAP Chao et al. (1999)
Plant Physiol 120: 979-992); a chemically-inducible pro
moter from tobacco, Pathogenesis-Related 1 (PR1) (induced
by salicylic acid and BTH (benzothiadiazole-7-carbothioic
acid S-methyl ester)); a tomato proteinase inhibitor II pro
moter (PIN2) or LAP promoter (both inducible with methyl
jasmonate); a heat shock promoter (U.S. Pat. No. 5,187.267);
a tetracycline-inducible promoter (U.S. Pat. No. 5,057,422);
and seed-specific promoters, such as those for seed storage
proteins (e.g., phaseolin, napin, oleosin, and a promoter for
soybean beta conglycin (Beachy et al. (1985) EMBO J. 4:
3047-3053)). In some preferred embodiments, the promoter
is a phaseolin promoter. All references cited herein are incor
porated in their entirety.
The expression cassettes may further comprise any
sequences required for expression of mRNA. Such sequences
include, but are not limited to transcription terminators,
enhancers such as introns, viral sequences, and sequences
intended for the targeting of the gene product to specific
organelles and cell compartments.
A variety of transcriptional terminators are available for
use in expression of sequences using the promoters of the
present invention. Transcriptional terminators are responsible
for the termination of transcription beyond the transcript and
its correct polyadenylation. Appropriate transcriptional ter
minators and those which are known to function in plants
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include, but are not limited to, the CaMV 35S terminator, the

tml terminator, the pea rbcS E9 terminator, and the nopaline
and octopine synthase terminator (See e.g., Odelletal. (1985)
Nature 313:810; Rosenberg et al. (1987) Gene, 56:125;
Guerineau et al. (1991) Mol. Gen. Genet., 262:141; Proudfoot
(1991) Cell, 64:671; Sanfacon et al. Genes Dev. 5:141;
Mogen et al. (1990) Plant Cell, 2:1261; Munroe et al. (1990)
Gene, 91:151; Ballad et al. (1989) Nucleic Acids Res.
17:7891; Joshi et al. (1987) Nucleic Acid Res., 15:9627).
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In addition, in some embodiments, constructs for expres
sion of the gene of interest include one or more of sequences
found to enhance gene expression from within the transcrip
tional unit. These sequences can be used in conjunction with
the nucleic acid sequence of interest to increase expression in
plants. Various intron sequences have been shown to enhance
expression, particularly in monocotyledonous cells. For
example, the introns of the maize Adh1 gene have been found
to significantly enhance the expression of the wild-type gene
under its cognate promoter when introduced into maize cells
(Calais et al. (1987) Genes Develop. 1: 1183). Intron
sequences have been routinely incorporated into plant trans
formation vectors, typically within the non-translated leader.
In some embodiments of the present invention, the con
struct for expression of the nucleic acid sequence of interest
also includes a regulator Such as a nuclear localization signal
(Calderone et al. (1984) Cell 39:499; Lassoer et al. (1991)
Plant Molecular Biology 17:229), a plant translational con
sensus sequence (Joshi (1987) Nucleic Acids Research
15:6643), an intron (Luehrsen and Walbot (1991) Mol. Gen.
Genet. 225:81), and the like, operably linked to the nucleic
acid sequence encoding ADS.
In preparing a construct comprising a nucleic acid
sequence encoding a RNAi gene of the present invention,
various DNA fragments can be manipulated, so as to provide
for the DNA sequences in the desired orientation (e.g., sense
orantisense) orientation. For example, adapters or linkers can
be employed to join the DNA fragments or other manipula
tions can be used to provide for convenient restriction sites,
removal of superfluous DNA, removal of restriction sites, or
the like. For this purpose, in vitro mutagenesis, primer repair,
restriction, annealing, resection, ligation, or the like is pref
erably employed, where insertions, deletions or substitutions
(e.g., transitions and transversions) are involved.
Numerous transformation vectors are available for plant
transformation. The selection of a vector for use will depend
upon the preferred transformation technique and the target
species for transformation. For certain target species, differ
ent antibiotic or herbicide selection markers are preferred.
Selection markers used routinely in transformation include
the nptII gene which confers resistance to kanamycin and
related antibiotics (Messing and Vierra (1982) Gene 19: 259;
Bevan et al. (1983) Nature 304:184), the bar gene which
confers resistance to the herbicide phosphinothricin (White et
al. (1990) Nucl Acids Res. 18:1062: Spencer et al. (1990)
Theor. Appl. Genet. 79:625), the hph gene which confers
resistance to the antibiotic hygromycin (Blochlinger and
Diggelmann (1984) Mol. Cell. Biol. 4:2929), and the dhfr
gene, which confers resistance to methotrexate (Bourouis et
al. (1983) EMBO.J., 2:1099).
In some preferred embodiments, the vector is adapted for
use in an Agrobacterium mediated transfection process (See
e.g., U.S. Pat. Nos. 5,981,839; 6,051,757; 5,981,840; 5,824,
877; and 4,940,838; all of which are incorporated herein by
reference). Construction of recombinant Ti and Ri plasmids
in general follows methods typically used with the more
common bacterial vectors, such as pBR322. Additional use
can be made of accessory genetic elements sometimes found
with the native plasmids and sometimes constructed from
foreign sequences. These may include but are not limited to
structural genes for antibiotic resistance as selection genes.
There are two systems of recombinant Ti and Ri plasmid
vector systems now in use. The first system is called the
"cointegrate” system. In this system, the shuttle vector con
taining the gene of interest is inserted by genetic recombina
tion into a non-oncogenic Tiplasmid that contains both the
cis-acting and trans-acting elements required for plant trans
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formation as, for example, in the pMLJ1 shuttle vector and
the non-oncogenic Tiplasmid pGV3850. The second system
is called the “binary” system in which two plasmids are used;
the gene of interest is inserted into a shuttle vector containing
the cisacting elements required for plant transformation. The
other necessary functions are provided in trans by the non
oncogenic Tiplasmid as exemplified by the pBIN19 shuttle
vector and the non-oncogenic Tiplasmid PAL4404. Some of
these vectors are commercially available.
In other embodiments of the invention, the nucleic acid

sequence of interest is targeted to a particular locus on the
plant genome. Site-directed integration of the nucleic acid
sequence of interest into the plant cell genome may be
achieved by, for example, homologous recombination using
Agrobacterium-derived sequences. Generally, plant cells are
incubated with a strain of Agrobacterium which contains a
targeting vector in which sequences that are homologous to a
DNA sequence inside the target locus are flanked by Agro
bacterium transfer-DNA (T-DNA) sequences, as previously
described (U.S. Pat. No. 5,501,967). One of skill in the art
knows that homologous recombination may be achieved
using targeting vectors which contain sequences that are
homologous to any part of the targeted plant gene, whether
belonging to the regulatory elements of the gene, or the cod
ing regions of the gene. Homologous recombination may be
achieved at any region of a plant gene So long as the nucleic
acid sequence of regions flanking the site to be targeted is

10
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known.

In yet other embodiments, the nucleic acids of the present
invention are utilized to construct vectors derived from plant
(+)RNA viruses (e.g., brome mosaic virus, tobacco mosaic
virus, alfalfa mosaic virus, cucumber mosaic virus, tomato
mosaic virus, and combinations and hybrids thereof). Gener
ally, the inserted ADS polynucleotide of the present invention
can be expressed from these vectors as a fusion protein (e.g.,
coat protein fusion protein) or from its own Subgenomic
promoter or other promoter. Methods for the construction and

30
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use of such viruses are described in U.S. Pat. Nos. 5,846,795;
5,500,360; 5,173,410; 5,965,794; 5,977,438; and 5,866,785,

all of which are incorporated herein by reference.
In some embodiments of the present invention the nucleic
acid sequence of interest is introduced directly into a plant.
One vector useful for direct gene transfer techniques in com
bination with selection by the herbicide Basta (or phosphino
thricin) is a modified version of the plasmid pCIB246, with a
CaMV 35S promoter in operational fusion to the E. coli GUS
gene and the CaMV 35S transcriptional terminator (WO
93/07278).
3. Transformation Techniques
Once a nucleic acid sequence encoding an ADS of the
present invention is operatively linked to an appropriate pro
moter and inserted into a suitable vector for the particular
transformation technique utilized (e.g., one of the vectors
described above), the recombinant DNA described above can
be introduced into the plant cell in a number of art-recognized
ways. Those skilled in the art will appreciate that the choice of
method might depend on the type of plant targeted for trans
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formation. In some embodiments, the vector is maintained

episomally. In other embodiments, the vector is integrated
into the genome.
In some embodiments, the vector is introduced through
ballistic particle acceleration using devices (e.g., available
from Agracetus, Inc., Madison, Wis. and Dupont, Inc., Wilm
ington, Del.). (See e.g., U.S. Pat. No. 4,945.050; and McCabe
etal. (1988) Biotechnology 6:923). See also, Weissinger et al.
(1988) Annual Rev. Genet. 22:421; Sanford et al. (1987)
Particulate Science and Technology, 5:27 (onion); Svab et al.
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(1990) Proc. Natl. Acad. Sci. USA, 87:8526 (tobacco chlo
roplast); Christou et al. (1988) Plant Physiol. 87:671 (soy
bean); McCabe et al. (1988) Bio/Technology 6:923 (soy
bean): Kleinet al. (1988) Proc. Natl. Acad. Sci. USA,85:43.05
(maize): Klein et al. (1988) Bio/Technology, 6:559 (maize):
Klein et al. (1988) Plant Physiol.,91:4404 (maize): Fromm et
al. (1990) Bio/Technology, 8:833; and Gordon-Kamm et al.
(1990) Plant Cell. 2:603 (maize): Koziel et al. (1993) Bio
technology, 11:194 (maize); Hill et al. (1995) Euphytica,
85:119 and Koziel et al. (1996) Annals of the New York
Academy of Sciences 792: 164; Shimamoto et al. (1989)
Nature 338: 274 (rice); Christou et al. (1991) Biotechnology,
9:957 (rice); Datta et al. (1990) Bio/Technology 8:736 (rice);
European Patent Application EP 0332 581 (orchardgrass and
other Pooideae); Vasil et al. (1993) Biotechnology, 11: 1553
(wheat); Weeks et al. (1993) Plant Physiol., 102: 1077
(wheat); Wan et al. (1994) Plant Physiol. 104:37 (barley);
Jahne et al. (1994) Theor. Appl. Genet. 89:525 (barley);
Knudsen and Muller (1991) Planta, 185:330 (barley);
Umbecket al. (1987) Bio/Technology 5: 263 (cotton); Casas
etal. (1993) Proc. Natl. Acad. Sci. USA90:11212 (sorghum);
Somers et al. (1992) Bio/Technology 10:1589 (oat); Torbert
et al. (1995) Plant Cell Reports, 14:635 (oat); Weeks et al.
(1993) Plant Physiol., 102:1077 (wheat); Chang et al., WO
94/13822 (wheat) and Nehra et al. (1994) The Plant Journal,
5:285 (wheat).
In other embodiments, direct transformation in the plastid
genome is used to introduce the vector into the plant cell (See
e.g., U.S. Pat. Nos. 5,451,513; 5,545,817: 5,545,818; PCT
application WO95/16783). The basic technique for chloro
plast transformation involves introducing regions of cloned
plastid DNA flanking a selectable marker together with the
nucleic acid encoding the RNA sequences of interest into a
Suitable target tissue (e.g., using biolistics or protoplast trans
formation with calcium chloride or PEG). The 1 to 1.5 kb
flanking regions, termed targeting sequences, facilitate
homologous recombination with the plastid genome and thus
allow the replacement or modification of specific regions of
the plastome. Initially, point mutations in the chloroplast 16S
rRNA and rps 12 genes conferring resistance to spectinomy
cin and/or streptomycin are utilized as selectable markers for
transformation (Svab et al. (1990) PNAS, 87:8526; Staub and
Maliga, (1992) Plant Cell, 4:39). The presence of cloning
sites between these markers allowed creation of a plastid
targeting vector introduction of foreign DNA molecules
(Staub and Maliga (1993) EMBO J., 12:601). Substantial
increases in transformation frequency are obtained by
replacement of the recessive rRNA or r-protein antibiotic
resistance genes with a dominant selectable marker, the bac
terial aadA gene encoding the spectinomycin-detoxifying
enzyme aminoglycoside-3'-adenyltransferase (Svab and
Maliga (1993) PNAS,90:913). Other selectable markers use
ful for plastid transformation are known in the art and encom
passed within the scope of the present invention. Plants
homoplasmic for plastid genomes containing the two nucleic
acid sequences separated by a promoter of the present inven
tion are obtained, and are preferentially capable of high
expression of the RNAs encoded by the DNA molecule.
In other embodiments, vectors useful in the practice of the
present invention are microinjected directly into plant cells by
use of micropipettes to mechanically transfer the recombi
nant DNA (Crossway (1985) Mol. Gen. Genet, 202:179). In
still other embodiments, the vector is transferred into the
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plant cell by using polyethylene glycol (Krens et al. (1982)
Nature, 296:72; Crossway et al. (1986) BioTechniques,
4:320): fusion of protoplasts with other entities, either mini
cells, cells, lysosomes or other fusible lipid-surfaced bodies

US 7,803,984 B2
29
(Fraley et al. (1982) Proc. Natl. Acad. Sci., USA, 79:1859);
protoplast transformation (EPO 292.435); direct gene transfer
(Paszkowski et al. (1984) EMBO J., 3:2717: Hayashimoto et
al. (1990) Plant Physiol. 93:857).
In still further embodiments, the vector may also be intro
duced into the plant cells by electroporation (Fromm, et al.
(1985) Proc. Natl Acad. Sci. USA 82:5824; Riggs et al.
(1986) Proc. Natl. Acad. Sci. USA 83:5602). In this tech
nique, plant protoplasts are electroporated in the presence of
plasmids containing the gene construct. Electrical impulses
of high field strength reversibly permeabilize biomembranes
allowing the introduction of the plasmids. Electroporated
plant protoplasts reform the cell wall, divide, and form plant
callus.

10

15

In addition to direct transformation, in some embodiments,

animals results in a decrease in nematode infestation of the

the vectors comprising a nucleic acid sequence encoding a
RNAi gene of the present invention are transferred using
Agrobacterium-mediated transformation (Hinchee et al.
(1988) Biotechnology, 6:915: Ishida et al. (1996) Nature Bio
technology 14:745). Agrobacterium is a representative genus
of the gram-negative family Rhizobiaceae. Its species are
responsible for plant tumors such as crown gall and hairy root
disease. In the dedifferentiated tissue characteristic of the

tumors, amino acid derivatives known as opines are produced
and catabolized. The bacterial genes responsible for expres
sion of opines area convenient source of control elements for
chimeric expression cassettes. Heterologous genetic
sequences (e.g., nucleic acid sequences operatively linked to
a promoter of the present invention), can be introduced into
appropriate plant cells, by means of the Tiplasmid of Agro
bacterium tumefaciens. The Tiplasmid is transmitted to plant
cells on infection by Agrobacterium tumefaciens, and is sta
bly integrated into the plant genome (Schell (1987) Science,
237: 1176). Species which are susceptible infection by Agro
bacterium may be transformed in vitro. Alternatively, plants
may be transformed in vivo. Such as by transformation of a
whole plant by Agrobacteria infiltration of adult plants, as in
a “floral dip” method (Bechtold N, Ellis J. Pelletier G (1993)
Cr. Acad. Sci. III-Vie 316: 1194-1199).
4. Regeneration
After selecting for transformed plant material that can
express the heterologous gene encoding a RNAi gene of the
present invention, whole plants are regenerated. Plant regen
eration from cultured protoplasts is described in Evans et al.
(1983) Handbook of Plant Cell Cultures, Vol. 1: (MacMillan
Publishing Co. New York); and Vasil I. R. (ed.), Cell Culture

animals. Suitable methods for formulating feed are well
known in the art. Feeds for a variety of animals may be
formulated, including but not limited to, pigs, cattle, sheep,
chickens, turkeys and other poultry, fish, horses, dogs, cats,
and rabbits.
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and Somatic Cell Genetics of Plants, Acad. Press, Orlando,

Vol. I (1984), and Vol. III (1986). It is known that many plants
can be regenerated from cultured cells or tissues, including
but not limited to all major species of Sugarcane, Sugar beet,
cotton, fruit and other trees, legumes and vegetables, and
monocots (e.g., the plants described above). Means for regen
eration vary from species to species of plants, but generally a
Suspension of transformed protoplasts containing copies of
the heterologous gene is first provided. Callus tissue is
formed and shoots may be induced from callus and Subse
quently rooted.
Alternatively, embryo formation can be induced from the
protoplast Suspension. These embryos germinate and form
mature plants. The culture media will generally contain vari
ous amino acids and hormones, such as auxin and cytokinins.
Shoots and roots normally develop simultaneously. Efficient
regeneration will depend on the medium, on the genotype,
and on the history of the culture. The reproducibility of regen
eration depends on the control of these variables.

30
5. Generation of Transgenic Lines
Transgenic lines are established from transgenic plants by
tissue culture propagation. The presence of nucleic acid
sequences encoding a RNAi gene of the present invention
(including mutants or variants thereof) may be transferred to
related varieties by traditional plant breeding techniques.
These transgenic lines are then utilized for evaluation of oil
production and other agronomic traits.
III. Animal Feeds Containing dsRNA Molecules
The present invention provides animals feeds comprising
dsRNA molecules derived from plants. In some embodi
ments, the dsRNA molecules are present in seeds and seed
products derived from the transgenic plants described above.
It is contemplated that providing feed containing dsRNA to
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In other embodiments, the transgenic plant material is
encapsulated. For example, in Some embodiments, tablets or
capsules of the present invention are coated with an enteric
coating which dissolves at a pH of about 6.0 to 7.0. A suitable
enteric coating which dissolves in the Small intestine but not
in the stomach is cellulose acetate phthalate. Further details
on techniques for formulation for and administration and
administration may be found in the latest edition of Reming
ton's Pharmaceutical Sciences (Maack Publishing Co., Eas
ton, Pa.).
In further embodiments, the present invention provides
pharamaceutical compositions comprising transgenic plant
material derived from transgenic plants expressing a nema
tode double stranded RNA. In some embodiments, the phar
maceutical compositions of the present invention can be for
mulated using pharmaceutically acceptable carriers well
known in the art in dosages Suitable for oral administration.
Such carriers enable the pharmaceutical compositions to be
formulated as tablets, pills, capsules, liquids, gels, syrups,
slurries, Suspensions and the like, for oral or nasal ingestion
by a subject to be treated.
Pharmaceutical compositions suitable for use in the
present invention include compositions wherein the active
ingredients are contained in an effective amount to achieve
the intended purpose. Determination of effective amounts is
well within the capability of those skilled in the art, especially
in light of the disclosure provided herein. In some embodi
ments, a therapeutically effective dose refers to that amount
of plant material that ameliorates symptoms of the disease
state (i.e., nematode infestation). Toxicity and therapeutic
efficacy of Such compounds can be determined by standard
pharmaceutical procedures in in vitro models or experimental
animals, e.g., for determining the LDso (the dose lethal to
50% of the population)and the EDs (the dose therapeutically
effective in 50% of the population). The dose ratio between
toxic and therapeutic effects is the therapeutic index, and it
can be expressed as the ratio LDso/EDso. Compounds that
exhibit large therapeutic indices are preferred. The data
obtained from these cell culture assays and additional animal
studies can be used in formulating a range of dosage for
human use. The dosage of Such compounds lies preferably
within a range of circulating concentrations that include the
EDs with little or no toxicity. The dosage varies within this
range depending upon the dosage form employed, sensitivity
of the patient, and the route of administration.
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In addition to the active ingredients these pharmaceutical
compositions may contain Suitable pharmaceutically accept
able carriers comprising excipients and auxiliaries that facili
tate processing of the active compounds into preparations that
can be used pharmaceutically. The preparations formulated
for oral administration may be in the form of tablets, dragees,
capsules, or solutions.
The pharmaceutical compositions of the present invention
may be manufactured in a manner that is itself known (e.g., by
means of conventional mixing, dissolving, granulating, dra
gee-making, levigating, emulsifying, encapsulating, entrap
ping or lyophilizing processes).
Pharmaceutical formulations for parenteral administration
include aqueous solutions of the active compounds in water
soluble form. Additionally, Suspensions of the active com
pounds may be prepared as appropriate oily injection Suspen
sions. Suitable lipophilic solvents or vehicles include fatty
oils such as sesame oil, or synthetic fatty acid esters. Such as
ethyl oleate or triglycerides, or liposomes. Aqueous injection
Suspensions may contain Substances that increase the viscos
ity of the Suspension, such as sodium carboxymethyl cellu
lose, Sorbitol, or dextran. Optionally, the Suspension may also
contain Suitable stabilizers or agents that increase the Solu
bility of the compounds to allow for the preparation of highly
concentrated Solutions.

Pharmaceutical preparations for oral use can be obtained
by combining the active compounds with Solid excipient,
optionally grinding a resulting mixture, and processing the
mixture of granules, after adding Suitable auxiliaries, if
desired, to obtain tablets or dragee cores. Suitable excipients
are carbohydrate or protein fillers such as Sugars, including
lactose, sucrose, mannitol, or sorbitol; starch from corn,
wheat, rice, potato, etc.; cellulose Such as methyl cellulose,
hydroxypropylmethyl-cellulose, or sodium carboxymethyl
cellulose; and gums including arabic and tragacanth; and
proteins such as gelatin and collagen. If desired, disintegrat
ing or solubilizing agents may be added, such as the cross
linked polyvinyl pyrrolidone, agar, alginic acid or a salt
thereof such as Sodium alginate.
Dragee cores are provided with Suitable coatings Such as
concentrated Sugar Solutions, which may also contain gum
arabic, talc, polyvinylpyrrolidone, carbopolgel, polyethylene
glycol, and/or titanium dioxide, lacquer Solutions, and Suit
able organic solvents or solvent mixtures. Dyestuffs or pig
ments may be added to the tablets or dragee coatings for
product identification or to characterize the quantity of active
compound, (i.e., dosage).
Pharmaceutical preparations that can be used orally
include push-fit capsules made of gelatin, as well as Soft,
sealed capsules made of gelatin and a coating Such as glycerol
or Sorbitol. The push-fit capsules can contain the active ingre

5

Construction of Major Sperm Protein RNAi Gene
10

This Example describes the construction of the expression
construct for MSP dsRNA for use in RNAi. Conserved
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library and sequenced. This sequence is presented in FIG.1 as
SEQID NO:1. A T7 primer (5'gtaata cgactic actataggg c 3';
SEQID NO:2) and MSP specific primer (5' cca tpgctgcag
gcc ttcaag acc ac 3'; SEQ ID NO:3: reverse compliment
identified by double underline in FIG.1) were used to amplify
an approximately 600 base pair fragment of MSP. The MSP
specific primer (SEQ ID NO:3) was designed to introduce
NcoI (CCATGG) and PstI (CTGCA'G) sites at the 5' end of
the amplified product. The resulting amplified fragment was
then subcloned into pGEM-T. The subcloned sequence was
then excised from the vector by digestion with BamHI and
EcoRI to provide SEQID NO: 45 (FIG. 2B). The EcoRI site
is located in the pGEM-T vector, while the BamHI site is
located in the MSP coding region. The resulting fragment was
then digested with XhoI and PstI to provide SEQ ID NO:4
(FIG. 2A). The reverse complement of SEQ ID NO:4 is
provided in FIG.3 as SEQID NO:5. SEQID NOS:45 and 5
were then sequentially cloned into pGEM37f(+) into EcoRI/
BamHI and Sall/PstI sites to provide the assembled MSPi
sequence (SEQID NO:6; FIG. 4; the loop sequence separat
ing the sense and antisense sequences is underlined).
The MSPi sequence was removed excised from the plas
mid by a NcoI/HindIII digest and cloned into pATACTCV
(Arabidopisis actin-2 promoter (An et al., Strong, constitutive
expression of the Arabidopsis ACT2/ACT8 actin subclass in
vegetative tissues. Plant Journal, 10 (1): 107-121 (1996)) to
provide plasmid (p ATMSPi). The NcoI site is at the 5' end of
pATMSPi, while the HindIII site is at the 3' end of the plas
mid.

Example 2
RNA Polymerase II Construct Design
55

without stabilizers.
EXPERIMENTAL
60

The following examples are provided in order to demon
strate and further illustrate certain preferred embodiments
and aspects of the present invention and are not to be con
Strued as limiting the scope thereof.
In the experimental disclosures which follow, the follow
ing abbreviations apply: N (normal); M (molar); mM (milli
molar); LM (micromolar); mol (moles); mmol (millimoles);

regions of the MSP gene for various nematodes were found
using “Block Maker. Degenerate primers were synthesized
and apartial gene fragment was amplified from SCN genomic
DNA. The fragment was cloned into pGEM-T Easy vector,
sequenced, and used for a BLAST search in GenBank. The
cloned sequence showed homology with MSP genes from
other nematodes. The fragment was used to probe a cDNA
library made from J2juveniles.
A subclone was identified in a SCNJ2 cDNA lambda

dients mixed with a filler or binders such as lactose or

starches, lubricants such as talc or magnesium Stearate, and,
optionally, stabilizers. In soft capsules, the active compounds
may be dissolved or Suspended in Suitable liquids, such as
fatty oils, liquid paraffin, or liquid polyethylene glycol with or
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umol (micromoles); nmol (nanomoles); pmol (picomoles); g
(grams); mg (milligrams); Lug (micrograms), ng (nanograms);
1 or L (liters); ml (milliliters); ul (microliters); cm (centime
ters); mm (millimeters); um (micrometers); nm (nanom
eters); C. (degrees Centigrade).
Example 1
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This Example describes the construction of an RNA poly
merase II RNAi gene. Degenerate primers were used to
retrieve RNA polymerase II sequence from H. glycines. Since
H. glycines RNA polymerase II sequence was unknown, the
primers had to be designed using sequence from C. elegans
and three other related organisms-Artemia Salina (brine
shrimp), Helobdella Stagnalis (leech), and Ilyanassa obsolete
(eastern mud snail). The RNA polymerase II sequences of
these four organisms were copied into Blockmaker (blocks
..fhcrc.org). The blocks formed from Blockmaker were then
copied into Codehop to make degenerate primers. The
sequences were also copied into Clustalw, which, like Block
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maker, is a multiple sequence alignment tool. The advantage
of using Clustalw is that it provides a view of the entire
alignment of the sequences rather than just blocks of align
ments. Clustalw also points out regions of the alignment that
have very tight homology throughout the different organisms.
Codehop constructs degenerate primers from the blocks
assembled in Blockmaker. Degenerate primers were chosen
that had tight homology in the sequence alignments in Clust
alw, a GC content greater than 45%, degeneracy no greater
than 16, and amino acids in the 3' end of the primer that are
coded for by only 1 or 2 codons.
The degenerate primer pair dRP2L F/dRP2T R1 was cho
Sen from the degenerate primers made in Codehop.
dRP2L F primer:

34
(SEQ ID NO: 11)
5

RP2 KpnF1B primer: GACGGTACCGGCAGTGTCAATGTTATCCGAAC
32mer-This primer adds a Kipn I site to the anti
SeeSee

fragment (underlined)
(SEQ ID NO:12)
10

RP2 BamRB primer: ATCGGATCCTCCAATGGTGTGTCCCTCGG
29mer-This primer adds a Bam HI site to the anti
SeeSee

fragment (underlined)

5'- CCA ACC CTG CAC AAA ATG WSN ATG ATG-3' 27mer. (SEO ID NO : 7)

dRP2T R1 primer: 5' - CAG AAT TCG GTT CAC TTG RTT YTC RAA-3' 27mer. (SEQ ID NO:8)

The dRP2L F/dRP2T R1 primer pair successfully ampli
fied an ~1.0 kilobase fragment from genomic H. glycines
DNA. The fragment was cloned into a PGEM-T-easy vector
and five clones were found to have the ~1.0kb fragment. Each
of the clones were sequenced using SP6 and T7. The sequence
of the clones was identical. One of the clones was randomly
chosen for further sequence analysis. The sequence of this
clone is provided FIG. 5 as SEQID NO:9.
SEQID NO:9 was used in a blastx search which compared
it to a protein database (ncbi.nlm.nih.gov/BLAST/). The
blastx search confirmed that the sequence of clone 6 was RNA
polymerase II. Thlastx was also used which blasted the
degenerate nucleotide sequence against a translated database.
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TblastX aided in the location of exons and introns in the

degenerate sequence. It was necessary to locate the exon
regions of the sequence because the construct must be
designed from regions that are transcribed (i.e. exons). From

40

tblastX, it was estimated that an exon occurred between base

pair 555 and base pair 834 in the degenerate sequence. This
279 base pair exon region is provided in FIG. 6 as SEQ ID
NO:10. This exon sequence was blasted against a protein
database (blastx) to confirm that the exon was RNA poly
merase II and also against the translated database (tblastX) to
insure that the sequence was indeed an exon.
Since all plants and mammals possess RNA polymerase II,
it was necessary to choose an exon that whose sequence
shows low homology to any other organisms, besides maybe
C. elegans. If an exon was chosen that demonstrated tight
homology to other non-target organisms then RNA poly
merase II may also be shut down in those organisms. When
the above exon nucleotide sequence was blasted against other
nucleotide sequence in the database (blastin), very little
homology was demonstrated with any other organism besides
C. elegans. From the various blast searches, it was decided
that the antisense and sense fragments of the construct would
be designed from this exon region.

45

instead of a Bam HI site.
50

(SEQ ID NO: 15)

RP2 KpnF2B primer: TGAGGTACCGACGAAGACAGCGGACCATAC
3 Omer-The primer adds a Kipn I site to the sense
fragment (underlined)
(SEQ ID NO: 16)
55

60

The antisense-sense construct was cloned into the Bam HI

and Kpn I sites of a puC 119 based vector which possesses a
35S promoter and nos terminator regions necessary for gene
expression in Soybeans. Briefly, the primer pair
RP2 KpnF1B/RP2 BamRB was designed to amplify a 273
bp antisense fragment from the exon region shown above.

The 285 bp fragment resulting from the amplification is pro
vided in FIG. 7 as SEQ ID NO:13. The amplified fragment
was cloned into pGEM-T-easy. The fragment was cut out of
pGEM-T-easy using Kpn I and Bam HI enzymes and subse
quently cloned behind the 35S promoter in the puC119 based
vector. The way the sequence is cloned into the vector is
actually the reverse complement of the above sequence. The
RP2 BamRB primer adds a BamHI site which is on the 5' end
of the fragment once cloned into the vector. The
RP2 KpnF1B primer adds a Kpn I site which is on the 3' end
of the fragment once cloned into the vector. The sequence of
the reverse complement is provided in FIG. 8 as SEQ ID
NO:14. FIG. 9 provides a pictoral representation of the clon
ing strategy. Positive clones containing the antisense frag
ment were designated pRS1 KpnF1B-BamRB.
The sense fragment was then cloned into Kpn I and Sac I
sites located behind the previously cloned antisense frag
ment. Briefly, a 243 bp sense fragment was amplified using
the primer pair RP2 KpnF2B/RP2 SacRB. The forward
primer RP2 KpnF2B is located 19 bp inside of the
RP2 KpnF1B primer and the reverse primer RP2 SacRB is
the same as the RP2 BamRB primer but adds a Sac I site

65

RP2 SacRB primer: TTCGAGCTCTCCAATGGTGTGTCCCTCGG
29mer-The primer adds a Sac I site to the sense
fragment (underlined)

The Kpn I and Sac I sites were added to sense fragment so that
it could be cloned directly behind the antisense fragment. The
sense fragment is provided in FIG.10 as SEQID NO:17. The
sequence amplified by these two primers is complementary to
the sequence of the antisense fragment found in pRS1
KpnF1B-BamRB clone 14. The sequence in bold is sequence
that is not complementary between the antisense and sense
fragments. This non-complementary sequence is necessary
so that the antisense and sense fragments are able to foldback
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onto one another and align during transcription, thus forming
double strand RNA. The cloning strategy is depicted in FIG.

36
In the second bioassay, residual effects of the MSPicon
struction upon nematodes were evaluated. Cysts from repli
cates of each event and non-engineered checks were pooled
independently and ground to release eggs. Eggs were then
added to sterilized soil at a concentration of 1000 eggs/plant.
“Flyer', a soybean variety with no resistance to SCN, was
planted in this infected soil and grown for six weeks. At the
end of the bioassay the roots were washed and data on cyst
and egg production and root weight was recorded. Results are

11.

Example 3
Chitin Synthase Constructs
This Example describes the construction of a chitin syn
thase RNAi gene. Chitin synthase gene was selected because
in RNAi experiments by Piano et al. (Piano F. Schetter A.J.
Mangone M. Stein L. D. Kemphues K J. RNAi analysis of
genes expressed in the ovary of Caenorhabditis elegans. Cur
rent Biology 10: 1619) showed that silencing of this gene
prevents development of nematode progeny (i.e. embryo
lethal). The spliced sequenced together with Blockmaker
(blocks.fhere.org), Codehop, and Clustalw to make degener
ate primers and amplify the chitin synthase sequence from
Heterodera glycines. This sequence is providing in FIG. 12
(SEQID NO: 18). Sense and antisense fragments are cloned
from the underlined region using methods similar to those
described above. The sense and antisense fragments are then
cloned into vector as described in Example 2. Primers useful
for cloning the sense and antisense sequences include the
following:
CHSY15.1 F :

CCGATGCTTAGGCTGAC

(SEQ ID NO:19)

CHSY21 O. F.

CCAGCGGCAGTGATTC

(SEQ ID NO: 2O)

CHSY287 R:

AGCACACCTTCTCCAATC

(SEQ ID NO:21)

CHSY355 F:

TGGTACCAAAAGTTCGAGTAC

(SEO ID NO: 22)

CHSY4O9 F:

CATGTGTTCGGCTGTGT

(SEQ ID NO:23)

CHSYs43 R:

ATCGGGTCTTCGCCTTG

(SEQ ID NO:24)
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Example 4
Reduction in the Number of Cysts in Transgenic
Plants Expressing MSPi Gene
MSP is the major protein that required for nematode sperm
motility. If this protein is disrupted, male sterility will result
and female nematodes will not be fertilized and develop cysts.
These examples describe experiments wherein soybean
plants were genetically modified to express the MSPi con
struct described in Example 1. The results show a significant
reduction in the amount of cysts from the transgenic plants as
compared to the non-engineered controls.
Soybean Somatic embryos were genetically modified using
a particle gun to contain the pATMSPi construct (MSP
RNAi), multiplied in tissue culture, and converted to plants.
Several independent events from two cultivars were recov
ered containing this construction. The two cultivars were
“Jack', a partially resistant cultivar, and “Chapman' a sus
ceptible cultivar. Two bioassays were performed with these
transgenic lines.
In the first bioassay the MSP RNAi transgenic plants were
tested for SCN resistance. Events as well as non-engineered
controls were transplanted into soil infected with soybean
cyst nematodes (SCN) and grown in the greenhouse for six
weeks. Soybean roots were then washed to remove soil and
debris. SCN cysts were removed from each plant and the
number of cysts, eggs per cysts and root weight data was
collected for each replicate. Results are summarized in FIG.
13-18.
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Summarized in FIGS. 13-17.

Referring to FIG. 13, data from the first experiment shows
a slight reduction in the number of cyst per plant when com
pared to the non-engineered control. In the second experi
ment even though the eggs harvested from the first experi
ment were applied to susceptible line (Flyer) at the rate, a
39.3% reduction in cysts was recorded from eggs harvested
from the transgenic plants. Inference can be drawn from these
results that 1) the MSPi construction does inhibit the cysts
formation at a low level and 2) the effects of the transgene can
be carried over to the next generation.
Referring to FIG. 14, data from the first experiment shows
a 49.4% reduction in the number of cyst per gram of root
when compared to the non-engineered control. In the second
experiment a difference (34.0% reduction) was recorded.
Inference can be drawn from these results that 1) the MSPi
construction does inhibit the cysts formation at some level
and 2) the effects of the transgene can be carried over to the
next generation.
Referring to FIG. 15, data from the first experiment shows
a 35.5% reduction in the number of SCN eggs perplant when
compared to the non-engineered control. In the second
experiment even though the eggs of the first experiment were
applied to susceptible line (Flyer) at the same rate (1000 eggs
per plant) a significant difference (29.0% reduction) was
recorded in the eggs from the transgenic plants. SCN eggs
used for inoculation in Experiment 2 originated from eggs
collected in Experiment 1. SCN eggs from transgenic lines
were applied at the same rate. Inference can be drawn from
these results that 1) the MSPi construction does inhibit the
egg production at Some level and 2) the effects of the trans
gene was carried over to the next generation of SCN.
Referring to FIG. 16, data from the first experiment shows
a 32.5% reduction in the number of SCN eggs per gram root
when compared to the non-engineered control. In the second
experiment even though the eggs of the first experiment were
applied to susceptible line (Flyer) a significant difference
(25.1% reduction) was recorded. SCN eggs used for inocula
tion in Experiment 2 originated from eggs collected in
Experiment 1. SCN eggs from transgenic lines were applied
at the same rate. Inference can be drawn from these results

that 1) the MSPiconstruction does inhibit the egg production
at some level and 2) the effects of the transgene was carried
over to the next generation of SCN.
Referring to FIG. 17, data from the first experiment shows
a small reduction in the number of SCN eggs per cyst when
compared to the non-engineered control. This reduction was
not significant when the data was statistically analyzed. This
trend continued in the second experiment. Inference can be
drawn from these results that 1) the MSPi construction effect
the number of eggs per cyst when cyst develop and 2) the
effects of the transgene on eggs/cysts do not carry over to the
next generation of SCN.
In Summary, the results show that soybean plants trans
formed with the MSPRNAi construction do have significant
levels of resistance to Soybean cyst nematode. In addition,
SCN progeny obtained from roots of these plants have a
reduced ability to infect Susceptible cultivars suggesting
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retention of the phenotype. Transgenic plants containing the
MSP RNAi construction presumably cause a significant
amount of males to become sterile thereby reducing the
amount of cysts. It also appears the effect of the RNAi mol
ecules can be seen in the progeny of SCN feeding on the
nontransgenic plants.
All publications and patents mentioned in the above speci
fication are herein incorporated by reference. Various modi
fications and variations of the described method and system
of the invention will be apparent to those skilled in the art

SEQUENCE LISTING
<16 Os NUMBER OF SEO ID NOS: 45
<21 Os SEQ ID NO 1
&211s LENGTH: 1257
&212s. TYPE: DNA

<213> ORGANISM: Heterodera glycines
22 Os. FEATURE:

<221s NAMEAKEY: misc feature
<222s. LOCATION: (6) . . (6)

<223> OTHER INFORMATION: n is a, c, g, or t
22 Os. FEATURE:

<221s NAMEAKEY: misc feature
<222s. LOCATION: (42) ... (42)

<223> OTHER INFORMATION: n is a, c, g, or t
22 Os. FEATURE:

<221s NAMEAKEY: misc feature
<222s. LOCATION: (4 OO) . . (400)

<223> OTHER INFORMATION: n is a, c, g, or t
22 Os. FEATURE:

<221> NAME/KEY: misc feature
<222s. LOCATION: (406) ... (406)

<223> OTHER INFORMATION: n is a, c, g, or t
22 Os. FEATURE:

<221s NAMEAKEY: misc feature
<222s. LOCATION: (438) ... (438)

<223> OTHER INFORMATION: n is a, c, g, or t
22 Os. FEATURE:

<221s NAMEAKEY: misc feature
<222s. LOCATION: (466) . . (.466)

<223> OTHER INFORMATION: n is a, c, g, or t
22 Os. FEATURE:

<221s NAMEAKEY: misc feature
<222s. LOCATION: (526) . . (526)

<223> OTHER INFORMATION: n is a, c, g, or t
22 Os. FEATURE:

<221s NAMEAKEY: misc feature
<222s. LOCATION: (528) . . (528)

<223> OTHER INFORMATION: n is a, c, g, or t
22 Os. FEATURE:

<221s NAMEAKEY: misc feature
<222s. LOCATION: (538.) . . (538)

<223> OTHER INFORMATION: n is a, c, g, or t
22 Os. FEATURE:

<221s NAMEAKEY: misc feature
<222s. LOCATION: (558) . . (558)

<223> OTHER INFORMATION: n is a, c, g, or t
22 Os. FEATURE:

<221s NAMEAKEY: misc feature
<222s. LOCATION: (565) . . (565)

<223> OTHER INFORMATION: n is a, c, g, or t
22 Os. FEATURE:

<221s NAMEAKEY: misc feature
<222s. LOCATION: (568) . . (568)

<223> OTHER INFORMATION: n is a, c, g, or t
22 Os. FEATURE:

<221s NAMEAKEY: misc feature
<222s. LOCATION: (1165) . . (1165)

<223> OTHER INFORMATION: n is a, c, g, or t
22 Os. FEATURE:

<221s NAMEAKEY: misc feature
<222s. LOCATION: (1167) . . (1167)

<223> OTHER INFORMATION: n is a, c, g, or t

38
without departing from the Scope and spirit of the invention.
Although the invention has been described in connection with
specific preferred embodiments, it should be understood that
the invention as claimed should not be unduly limited to such
specific embodiments. Indeed, various modifications of the
described modes for carrying out the invention which are
obvious to those skilled in molecular biology, plant biology,
biochemistry, or related fields are intended to be within the
Scope of the following claims.
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- Continued

LENGTH: 27
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Synthetic
FEATURE:

NAMEAKEY: misc feature
LOCATION: (21) ... (21)

OTHER INFORMATION: n is a, c, g,
& 4 OO

o

SEQUENCE: 7

c caa.ccctgc acaaaatgws natgatg

27

SEQ ID NO 8
LENGTH: 27
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:

OTHER INFORMATION: Synthetic
<4 OOs, SEQUENCE: 8

cagaatticgg tt cactitgrt tytcraa

27

<210s, SEQ ID NO 9
LENGTH: 104.7
TYPE: DNA

ORGANISM: Heterodera glycines
FEATURE:

NAMEAKEY: misc feature
LOCATION: (712) . . (712)

OTHER INFORMATION: n is a, c, g,

o

FEATURE:

NAMEAKEY: misc feature
LOCATION: (983) ... (983)

OTHER INFORMATION: n is a, c, g,

o

FEATURE:

NAMEAKEY: misc feature
LOCATION: (996) ... (996)

OTHER INFORMATION: n is a, c, g,

o

FEATURE:

NAMEAKEY: misc feature
LOCATION: (1044) . . (1044)

<223> OTHER INFORMATION: n is a, c, g,

o

<4 OOs, SEQUENCE: 9

c caa.ccctgc acaaaatgct atgatgggac atcgtgttaa ggcatgactg ttittatttgc

6O

aattgttatt ttggattatt acgatagatc ttaccttggit cgacttitt cq tatgaatttg

12 O

tcc.gtcacaa ccc cittacaa togctgattitt gacggggatg aaatgaatta gcacct tcc.g

18O

Caat cactgg agacacgggc agaaataaac galaattgcga tggitttittat taatttaaag

24 O

caccaaatat aaccct tacc ttitt citctaa aaaggcatct cgacagttaa ttacgc.caca

3OO

ggccaacaag C cagtgatgg gaattgttgca ggacacattg accgcagttc gaatgatgac

360

taaacg.cgac gtttittattg attacgct cq t ct catggat ttgttgatgc atttgccaaa
ttgggatgga aaaatticcgc agc.ca.gcgat aatcaaaccc aagcc actitt ggaccggaala
acaagttgttt acaaagataa titcCaggittt tdtcaaatga aacttitt cot coatt citttg

54 O

ttttgttcta actaaggcag togt caatgtt atc.cgaacac att cqaccca to cqgacgac
gaagacagcg gaccatacaa atggattt CC cctggcgaca c caaagtgct cattgagaac

660

agcgaactitc tict ctdggat aatttgttcc aaaactgttg gcagaggitt c Cngaalacctt

72 O

citt cacattgtc.gcattaga attgggtcat caaattgctg cc.gagittata tdccaacata
caaactgtta taaacgcatg gct tct coc gagggacaca c cattggaat tdgtttic cala

84 O

ttitt acttitt atttacaata attttgttta act ct caggit gacacaattig citgat acttic

9 OO
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<213> ORGANISM: Heterodera glycines
22 Os. FEATURE:

<221 > NAMEAKEY: misc feature
<222s. LOCATION: (123). . (123)
<223> OTHER INFORMATION: n is a
<4 OOs, SEQUENCE: 14

accalatt.cca atggtgttgtc Cct cqgcgag aagc.catgcg tittataa.ca.g tttgtatgtt

6O

ggcatataac toggcagdaa tittgatgacc

Caatt Ctaat

gcgacaatgt gaagaaggitt

12 O

t cnggaacct ctdccaacag ttittggaaca

aattatcCCa

gagagaagtt cgctgttctic

18O

aatgagcact ttggtgtc.gc Caggggaaat c catttgtat

citt cqtcgt.c

24 O

cggatgggtc gaatgtgttc ggata acatt gacactgcc

279

<210s, SEQ ID NO 15
&211s LENGTH: 30
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:
223 OTHER INFORMATION:

Synthetic

<4 OOs, SEQUENCE: 15

tgaggt accg acgalagacag cggaccatac

3O

<210s, SEQ ID NO 16
&211s LENGTH: 29
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:
223 OTHER INFORMATION:

Synthetic

<4 OOs, SEQUENCE: 16

titcgagct ct c caatggtgt gtc.cct cig

29

<210s, SEQ ID NO 17
&211s LENGTH: 279
&212s. TYPE: DNA

<213> ORGANISM: Heterodera glycines
22 Os. FEATURE:

<221 > NAMEAKEY: misc feature
<222s. LOCATION: (157) . . (157)
<223> OTHER INFORMATION: n is a
<4 OOs, SEQUENCE: 17

ggcagtgtca atgttatc.cg aacacatt cq acc catc.cgg acgacga aga Cagcggacca

6O

tacaaatgga titt cocctgg cgacaccaaa gtgct cattg agalacagcga

act tot ct ct

12 O

gggataattt gttccaaaac tgttggcaga ggttcCngaa

acct tott ca.

cattgtc.gca

18O

ttagaattgg gtcatcaaat tgctg.ccgag ttatatgc.ca

acatacaaac

tgttataaac

24 O

gcatggct tc. tcgc.cgaggg

acacaccatt

ggaattggit

<210s, SEQ ID NO 18
&211s LENGTH: 563
&212s. TYPE: DNA

<213> ORGANISM: Heterodera glycines
22 Os. FEATURE:

<221 > NAMEAKEY: misc feature
<222s. LOCATION: (507) ... (507)
<223> OTHER INFORMATION: n is a

C, g, or t

22 Os. FEATURE:

<221 > NAMEAKEY: misc feature
<222s. LOCATION: (52O) ... (52O)
<223> OTHER INFORMATION: n is a
22 Os. FEATURE:

<221 > NAMEAKEY: misc feature

C, g, or t

279
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<222s. LOCATION: (526). . (526)
<223> OTHER INFORMATION: n is a
<4 OOs, SEQUENCE: 18

Caagaaacga tiggtcc cagg tgatgtacat gtacttitttg Ctcgggcatc gaattatgga
Ctcacatttg agcgtagaag

acaaacaatt

gCaggtottt tgagcct aaa ttttgccctic

gtggaatctg. tcaataatt caatgttcgc accatgctt aggctgacaa

6O
12 O

Cacatatatt

18O

Ctcgc.cattg atggcgattic caaatticgaa Ccagcggcag tgatt cqtct tttacatctg

24 O

atgaacttga aaa.gcgacgt.

tgcggaagaa tccatcc.gat tggagalaggt

3OO

gtgctatoct tcc cattaat ggtgaattitc

ttaccatt co

cCagggg.tca tggitttggta

360

cCaaaagttc gagtacgcaa. tcqcc cattg gttcCaaaag gctgctgagc atgtgttcgg
Ctgtgttttgttgc.ccc.cg gtagcttct c tctgttt cqt gctitctgctic t catggatga
caatgtgatg cacaaataca c caaaantgc citc.cgaaccin acgacnattt tgttcagtat

54 O

gatcaaggcg aagaccc.gat gga

563

<210s, SEQ ID NO 19
&211s LENGTH: 17
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:
223 OTHER INFORMATION:

Synthetic

<4 OOs, SEQUENCE: 19

cc.gatgctta ggctgac

17

<210s, SEQ ID NO 2 O
&211s LENGTH: 16
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:
223 OTHER INFORMATION:

Synthetic

<4 OOs, SEQUENCE: 2O

Ccagcggcag tatto

16

<210s, SEQ ID NO 21
&211s LENGTH: 18
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:
223 OTHER INFORMATION:

Synthetic

<4 OOs, SEQUENCE: 21

agcacaccitt citccaatc

18

<210s, SEQ ID NO 22
&211s LENGTH: 21
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:
223 OTHER INFORMATION:

Synthetic

<4 OOs, SEQUENCE: 22

tggtaccalaa agttctgagta

c

<210s, SEQ ID NO 23
&211s LENGTH: 17
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

21

US 7,803,984 B2
61

62
- Continued

<221 > NAMEAKEY: misc feature
<222s. LOCATION: (76) . . (76)

<223> OTHER INFORMATION: n is a, c, g, or t
<4 OOs, SEQUENCE: 42

tctgtttcgt gcttctgctic ticatggatga caatgtgatg cacaaataca ccaaaantgc

6O

citcc.gaac Cn acgacnattt togttcagtat gat caaggcg
SEQ ID NO 43
LENGTH: 1.OO
TYPE: DNA

ORGANISM: Heterodera glycines
FEATURE:

NAMEAKEY: misc feature
LOCATION: (57) . . (57)

OTHER INFORMATION: n is a, c, g, or t
FEATURE:

NAMEAKEY: misc feature
LOCATION: (70) . . (70)

OTHER INFORMATION: n is a, c, g, or t
FEATURE:

NAMEAKEY: misc feature
LOCATION: (76) . . (76)

OTHER INFORMATION: n is a, c, g, or t
<4 OOs, SEQUENCE: 43

tctgtttcgt gcttctgctic ticatggatga caatgtgatg cacaaataca ccaaaantgc

6O

citcc.gaac Cn acgacnattt togttcagtat gat caaggcg
<210

SEQ ID NO 44

&211s LENGTH: 55
&212s. TYPE: DNA

<213> ORGANISM: Heterodera glycines
<4 OOs, SEQUENCE: 44

tctgtttcgt gcttctgctic ticatggatga caatgtgatg cacaaataca ccaaa

55

<210s, SEQ ID NO 45
&211s LENGTH: 389
&212s. TYPE: DNA

<213> ORGANISM: Heterodera glycines
22 Os. FEATURE:

<221 > NAMEAKEY: misc feature
<222s. LOCATION: (248) ... (248)

<223> OTHER INFORMATION: n is a, c, g, or t
22 Os. FEATURE

<221 > NAMEAKEY: misc feature
<222s. LOCATION: (254) ... (254)

<223> OTHER INFORMATION: n is a, c, g, or t
22 Os. FEATURE:

<221 > NAMEAKEY: misc feature
<222s. LOCATION: (286) ... (286)

<223> OTHER INFORMATION: n is a, c, g, or t
22 Os. FEATURE:

<221 > NAMEAKEY: misc feature
<222s. LOCATION: (314) ... (314)

<223> OTHER INFORMATION: n is a, c, g, or t
22 Os. FEATURE:

<221 > NAMEAKEY: misc feature
<222s. LOCATION: (353) ... (383)

<223> OTHER INFORMATION: n is a, c, g, or t
<4 OOs, SEQUENCE: 45

ggat CCtatc atgtcCatgt taggtgacg aag catcCtt C catcagacg ttgtactica

6O

tcggcaagtt Cttgcggcgc accatc.ccgt. Ct.ccctggala C cact cagc titgaacgtgg

12 O
18O

gcacgttggit C cacgc.cacg gtcacacggt Citcc ttggt gtc.ct cqctg ccdgggtca

24 O
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aggcgt Cinca gaanacggcc acgttgacag attcc tittgg gcc.ganic act CC9tc.cggcg

3OO

ggttcatgtt gatncgct tc ggtttggtgg tottgaaggc Ctgcagc.cat gginnnn.nnnn

360

nnngaattic

389

10

We claim:

1. A transgenic plant comprising a nucleic acid sequence
having a sense sequence linked to its complementary anti
sense sequence and encoding a double stranded RNA that
inhibits expression of a Heterodera glycines embryonic lethal
phenotype gene, wherein the sense or antisense sequence
comprises SEQID NO: 1, SEQID NO:9 or SEQID NO: 18,
wherein nematodes ingesting said double stranded nematode
RNA do not proliferate, and wherein said transgenic plant
exhibits increased resistance to soybean cyst nematodes as
compared to a control plant.
2. Seed from the transgenic plant of claim 1, wherein said
seed comprise said nucleic acid sequence.
3. A vector comprising a nucleic acid sequence having a
sense sequence linked to its complementary anstisense and
encoding a double stranded RNA sequence that inhibits
expression of a Heterodera glycines embryonic lethal pheno
type gene, wherein said sense sequence orantisense sequence
comprises SEQID NO: 1, SEQID NO:9 or SEQID NO: 18;
and wherein nematodes ingesting said double stranded nema
tode RNA do not proliferate.

15

25

12. The method of claim 11, wherein said nucleic acid

30

8. The vector of claim 3, wherein said nucleic acid

sequence comprises a sense sequence and its complementary
antisense sequence each operably linked to separate promot
CS.

sequence comprises a sense sequence and its complementary
antisense sequence operably linked to a plant promoter.
13. The method of claim 12, wherein said sense sequence
and said antisense sequence are operably linked to the same

promoter.
35

5. The vector of claim 3, wherein said nucleic acid

sequence comprises a sense sequence and its complementary
antisense sequence separated by a loop sequence.
6. The vector of claim 4, wherein said promoter is a tissue
specific promoter.
7. The vector of claim 4, wherein said promoter is a con
stitutive promoter.

11. The method of claim 10, wherein said nucleic acid

sequence is on a vector.

4. The vector of claim 3, wherein said nucleic acid

sequence comprises a sense sequence linked to its comple
mentary antisense sequence, said nucleic acid sequence being
operably linked to a plant promoter.

9. A transgenic Soybean plant comprising the vector of
claim 3; said transgenic soybean plant exhibits increased
resistance to soybean cyst nematodes as compared to a con
trol plant.
10. A method for controlling Heterodera glycines compris
ing providing a transgenic Soybean plant comprising a nucleic
acid sequence having a sense sequence linked to its comple
mentary anstisense and encoding a double stranded RNA that
inhibits expression of a Heterodera glycines embryonic lethal
phenotype gene, wherein the proliferation of nematodes feed
ing on said plant is reduced as compared to nematodes feed
ing on non-transgenic plant and wherein said sense sequence
or antisense sequence comprises SEQ ID NO: 1, SEQ ID
NO:9 and SEQID NO:18.

40

45

14. The method of claim 12, wherein said promoter is a
tissue specific promoter.
15. The method of claim 12, wherein said promoter is a
constitutive promoter.
16. The method of claim 10, wherein said sense sequence
and said antisense sequence are separated by a loop sequence.
17. A transgenic plant comprising a nucleic acid encoding
a double stranded RNA that causes decreased proliferation of
Soybean cyst nematodes feeding on said transgenic plant as
compared to soybean cyst nematodes feeding on non-trans
genic plants, wherein one strand of said double stranded RNA
is complementary to a nematode embryonic lethal phenotype
gene, and wherein said one strand comprises a sequence
selected from the group consisting of SEQID NO: 1, SEQID
NO:9 and SEQID NO: 18.
k
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